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ABSTRACT OF DISSERTATION 
 
DOPAMINE AND GLUTAMATE DYSFUNCTION IN A RODENT MODEL OF 
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: IMPLICATIONS FOR 
FUTURE NEUROPHARMACOLOGY 
 
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common 
disorders of childhood. It is theorized to be caused by catecholamine dysfunction 
in the striatum (Str) and frontal cortex (FC). The spontaneously hypertensive rat 
(SHR) has been used as a model for ADHD because of its attention deficits, 
impulsiveness, and hyperactivity. Prior studies of dopamine (DA) in the Str and FC 
have revealed conflicting results in the SHR compared to control, indicative of a 
need for a better understanding of DA dynamics in this model. In addition to the 
DA hypothesis, studies have begun implicating glutamate in the etiology of ADHD. 
Previous evaluations of the SHR model of ADHD found that the SHR have 
increased α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor activity and elevated calcium levels in the FC, suggesting that altered 
glutamatergic neurotransmission exists in the SHR. 
The first set of studies presented here suggest that increased surface 
expression of DA transporters may exist in the SHR model of ADHD, lowering 
basal DA levels. Second, we discovered that the glutamate system in the FC of 
the SHR model of ADHD is hyperfunctional, thus raising the possibility that 
targeting glutamate dysfunction in the FC could lead to the development of novel 
therapeutics for the treatment of ADHD. The third and fourth set of studies explored 
glutamate signaling in the awake rodent to fully understand glutamate 
neurotransmission as well as the effects of methylphenidate (MPH) on glutamate 
signaling in the prelimbic cortex, a region heavily implicated in ADHD. The SHR 
displayed similar phasic glutamate signaling compared to control; however, in the 
SHR but not the WKY control, chronic treatment with MPH lowered phasic 
glutamate amplitude. Additionally, intermediate treatment with MPH increased 
tonic glutamate in the SHR only, whereas chronic MPH treatment increased tonic 
levels in both the SHR and WKY compared to saline. 
Taken together, this body of work characterizes DA and glutamate signaling 
in the anesthetized SHR model of ADHD. Additionally, glutamate dynamics and 
the effects of the stimulant medication MPH were explored in the awake animal, 
providing evidence that glutamate is a likely target for future neuropharmacology 
for the treatment of ADHD. 
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Preface to Chapter One 
 The differences between human and rodent prefrontal cortices (PFC) are 
discussed through this chapter, and throughout this entire body of work. However, 
it must be noted that the two regions are not identical between species. Some do 
not even agree that the rodent has a PFC (Preuss 1995), but there is plenty of 
research to support the hypothesis that rodents possess a structure analogous to 
the human PFC (Seamans, Lapish et al. 2008). While referring to the PFC in the 
rodent in the following chapters, it’s important to note that the region being referred 
to is actually the frontal cortex.  
 
Chapter One: Introduction 
 
Attention-Deficit/Hyperactivity Disorder 
Attention-deficit/hyperactivity disorder (ADHD) is characterized by 
impulsivity, hyperactivity, inattention and cognitive impairment. The DSM-V 
classifies ADHD into 3 subtypes: predominantly inattentive type (ADHD-PI), 
predominantly hyperactive-impulsive type (ADHD-HI, the least commonly 
diagnosed type) and the most common subtype – combined (ADHD-C) (Paternite, 
Loney et al. 1995, Morgan, Hynd et al. 1996) – see Figure 1.1. ADHD is estimated 
to affect 6% of children worldwide and a portion of those diagnosed as children will 
continue to suffer into adulthood, affecting roughly 5% of adults (Kessler, Adler et 
al. 2006, Polanczyk, de Lima et al. 2007, Biederman, Petty et al. 2011). Children 
are three times more likely to repeat a year of classes and are more likely to drop 
1 
out of school compared to their normal peers (Barbaresi, Katusic et al. 2007, 
Barbaresi, Katusic et al. 2007, Froehlich, Lanphear et al. 2007), whereas 
adolescents and adults are more likely to suffer from mood and anxiety disorders 
and to develop drug addiction (Biederman, Petty et al. 2010). Hyperactivity has 
been found to lessen in adolescence, though cognitive impairment persists 
(Brassett-Harknett and Butler 2007, Spencer, Biederman et al. 2007). Those 
diagnosed with ADHD combined type (ADHD-C), characterized by hyperactivity 
and inattention, had larger impairments including lower grades in school and more 
arrests during adolescence compared to the other ADHD subtypes (inattentive and 
hyperactive/impulsive) (Molina, Hinshaw et al. 2009). Thus, evidence suggests the 
efficacy of treatments for adolescents could be improved and calls for a better 
understanding of the pathophysiology of ADHD, particularly for those diagnosed 
with ADHD-C. 
The Multimodal Treatment Study of Children with ADHD (MTA) followed 
children with ADHD for 14 months during treatment (behavior therapy alone, 
medication alone, or both) and roughly 8 years after its completion, when the 
participants were reaching late adolescence and young adulthood, it was 
discovered that more than 60% of children treated with medication during the initial 
14 month long MTA study had stopped taking any medication for their ADHD 
symptoms (Molina, Hinshaw et al. 2009). For these reasons, investigations into the 
neurobiological basis of ADHD in the adolescent population would greatly benefit 
these individuals if it were possible to better target their ADHD symptoms using 
novel pharmacotherapies. 
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ADHD and the Link to Neurochemistry 
When the Diagnostic and Statistical Manual of Mental Disorders (DSM-1) 
was first published in 1952, childhood psychiatric disorders were thought to be 
caused by environment and referred to as ‘reactions’ (Association 1952). It wasn’t 
until the DSM-2 was published in 1968 that ADHD began to be separated from 
general reactions and become its own diagnosis, referred to as the ‘hyperkinetic 
reaction of childhood.’ This reaction was characterized by a short attention span, 
hyperactivity, and restlessness (Association 1968), and in 1980, with the publication 
of the DSM-3, the ADHD diagnosis became more specific and was described as 
ADD (attention-deficit disorder) (Association 1980); however, by this time, this 
disorder was already being treated with stimulant medications, a treatment still used 
to this day. 
Stimulant medications were initially discovered to treat hyperactivity in the 
early 1900s when the psychiatrist Charles Bradley used amphetamines to treat 
children with headaches caused by pneumoencephalography and found it 
improved their school performance, social interactions and emotional responses. 
However, amphetamine as a treatment for ADHD was ignored until years later due 
to a variety of reasons (Strohl 2011). In the 1950s, researchers were beginning to 
look for the underlying mechanisms causing behavioral problems and it was at this 
time that Bradley’s discovery of amphetamine as a treatment for hyperactivity was 
uncovered and investigations into the mechanism of action of amphetamine began. 
The amphetamine formulation Bradley used in his patients was called Benzedrine, 
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a racemic mixture of 50/50 d- and l-amphetamine, produced by the company Smith, 
Kline and French (Strohl 2011). Treatment with this medication, in a variety of 
experimental paradigms, reduced hyperactivity (Robbins and Sahakian 1979); 
however, of particular note is a study published in 1976 showing decreased 
hyperactivity when treated with amphetamine in rodents with dopamine depletion 
(Shaywitz, Klopper et al. 1976). This was the first time that hyperactivity was linked 
to dopamine, but far from the last. Figure 1.2 illustrates the inverted U bell curve, 
first suggested by Yerkes and Dodson in 1908, though it was modified for 
performance and dopamine levels (Yerkes and Dodson 1908). As dopamine levels 
increase in the normal brain, so does performance (represented by the red box); 
however, in the ADHD brain, it is theorized that decreased dopamine levels are the 
cause behind decreased performance.  
 
Dopamine 
Dopamine was first suggested to function as a signaling molecule by Arvid 
Carlsson (Carlsson 1959). Previously, it has been thought that the role of dopamine 
was purely as a metabolic intermediate in the synthesis of norepinephrine and 
epinephrine. Dopamine, now classified as a catecholamine neurotransmitter, is 
produced in the cells of the substantia nigra (SN, A9) and ventral tegmental area 
(VTA, A10) of the midbrain and project to numerous brain regions, including the 
prefrontal cortex (PFC), striatum and nucleus accumbens (NA, see Figure 1.3). 
Projections from the VTA to the NA are identified as the mesolimbic pathway, or 
the “reward pathway,” because these dopamine projections are involved in 
4 
rewarding behaviors, (Schultz 2001) firing when a reward is greater than expected 
(Schultz 1986, Schultz 1998, Arias-Carrion and Poppel 2007). Projections from SN 
to the striatum are collectively referred to as the nigrostriatal pathway and play a 
role in many aspects of motor control (Iversen 2009). The mesocortical system 
consists of dopaminergic projections from the VTA to the PFC, and is implicated 
in many cognitive functions including, but most certainly not limited to, attention 
and memory (Iversen 2009).  
Dopamine is produced from tyrosine into 3,4-dihydroxyphenylalanine 
(DOPA) by the enzyme tyrosine hydroxylase. DOPA is then made into dopamine 
via DOPA-decarboxylase. Conversely, dopamine is enzymatically converted by a 
number of mechanisms: 1) dopamine-β-hydroxylase converts dopamine into 
norepinephrine, 2) monoamine oxidase (MAO) converts dopamine into 3,4-
dihydroxyphenylacetic acid (DOPAC), and 3) catechol-o-methyltransferase 
(COMT) catalyzes the formation of homovanillic acid (HVA). Dopamine-β-
hydroxylase only exists in norepinephrine neurons and thus will not be a focus in 
this work; however, MAO exists on the outer mitochondrial membrane in regions 
rich with catecholamines and is also thought to be in abundance extracellularly 
(Iversen 2009). Furthermore, COMT is mostly extracellular and plays a major role 
in regulating dopamine neurotransmission, especially in the prefrontal cortex 
(Iversen 2009). The final and most prominent method in which dopamine is cleared 
from the synapse is via the dopamine transporter (DAT). The DAT exists on the 
presynaptic neuron and can transport dopamine either into or out of the neuron, 
dependent upon the concentration gradient. It has been discovered that the 
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removal of dopamine from the synapse is predominantly performed by the DAT 
and not metabolism or diffusion (Cass, Zahniser et al. 1993). 
Intracellularly, dopamine is packaged into vesicles via the vesicular 
monoamine transporter (VMAT-2). The release of dopamine from the vesicle is 
Ca2+-dependent and occurs when an action potential raises the Ca2+ levels in the 
presynaptic neuron, causing vesicles stored with dopamine to bind to the cellular 
membrane and release its contents. The resulting synaptic dopamine is then able 
to bind to dopamine receptors on both the pre- and postsynaptic neurons. These 
receptors are classified into two major categories: 1) D1 receptors, consisting of D1 
and D5 and expressed postsynaptically, and 2) D2 receptors expressed both pre- 
and postsynaptically, consisting of D2 (short), D2 (long), D3 and D4. Stimulation of 
D1-type receptors causes increased cAMP production (activating), whereas 
stimulation of D2-type receptors causes inhibition of cAMP production (inhibiting). 
The effects of these receptors give dopamine the classification of a modulatory 
neurotransmitter. For a simplified PFC dopamine synapse diagram, see Figure 
1.4a. 
 
Glutamate 
Recent clinical evidence has implicated glutamate in the etiology of ADHD. 
This evidence stems from proton magnetic resonance spectroscopy studies of 
children and adults with ADHD. These studies have shown increased levels of a 
marker for combined glutamine/glutamate in the striatum and anterior cingulate 
cortex of the PFC compared to control peers (Carrey, MacMaster et al. 2002, 
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Moore, Biederman et al. 2006, Moore, Frazier et al. 2007). Based on this evidence, 
new investigations into glutamatergic functioning in ADHD are ongoing. 
Glutamate is the major excitatory neurotransmitter in the central nervous 
system and must be tightly regulated for proper neuronal signaling to occur 
(Danbolt 2001). Unlike dopamine, glutamate is in abundance in most all areas of 
the brain. Glutamate projections originating in the PFC extend to the striatum, NA, 
and the VTA and SN of the midbrain (see Figure 1.3). Glutamate is produced in 
the nerve terminals of these projections from two sources: 1) the Krebs cycle and 
2) glutamine transported via glial cells. Once produced, glutamate is transported 
into vesicles via the vesicular glutamate transporter (VGLUT) and when Ca2+ levels 
increase to cause an action potential, vesicles stored with glutamate bind to the 
cellular membrane and release their contents (Takamori 2006). Additionally, 
glutamate is released into the extracellular space via carrier mediated exchange 
with other amino acids (Jabaudon, Shimamoto et al. 1999, Jensen, Pickering et al. 
2000). Unlike with dopamine, there are no extracellular enzymes to degrade 
glutamate. Concentrations of extracellular glutamate are regulated in part by the 
uptake of glutamate via five high affinity sodium-dependent excitatory amino acid 
transporters (EAAT1, GLAST) (EAAT2, GLT-1), (EAAT3, EAAC), EAAT4, and 
EAAT5 (Danbolt 2001). The majority of glutamate uptake in the rodent brain is 
performed by two glial transporters, GLAST and GLT-1 (Rothstein, Dykes-Hoberg 
et al. 1996, Danbolt 2001). The glutamate taken up by the EAATs located on these 
glial cells is converted by glutamine synthetase into glutamine and transported out 
of the glial cell by system N transporter and taken up by the system A transporter 
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on the presynaptic neuron to help replenish glutamate levels through the 
mitochondrial bound glutaminase (Iversen 2009). Glutamate acts on synaptic 
glutamate receptors in the target brain region, which are classified into two major 
types: 1) ionotropic, which include the NMDA, AMPA and kainate receptors and 2) 
metabotropic, including the excitatory mGluRs 1 and 5 and the inhibitory mGluRs 
2, 3, 4, 6, 7, and 8. AMPA and kainate receptors are involved in fast 
neurotransmission. Glutamate binds producing a conformational change in both 
receptors allowing Na2+ influx into the postsynaptic neuron. Conversely, the NMDA 
receptor requires the binding of two ligands, glutamate and glycine, and also 
requires depolarization to release a Mg2+ block and allow Ca2+ into the postsynaptic 
neuron. Glutamate binding to AMPA and kainate receptors allows Na2+ into the cell, 
depolarizing the postsynaptic neuron and removing the Mg2+ block. mGluRs are G-
protein coupled receptors that use second messenger systems for signal 
transduction, and as such signaling is slower compared to the activation of 
ionotropic receptors. Group 1 (mGluR1 and mGluR5) is excitatory and located on 
postsynaptic glutamatergic neurons. Group 2 (mGluR2 and mGluR3) is inhibitory. 
mGluR2s are localized primarily on presynaptic glutamate neurons, whereas 
mGluR3s are located on glia and pre- and postsynaptic glutamatergic neurons. 
Finally, group 3 (mGluR4, mGluR6, mGlu7 and mGluR8) is inhibitory with mGluR4 
and mGluR7 located on both pre- and postsynaptic neurons (Schoepp 2001). For 
a simplified PFC glutamate synapse diagram, see Figure 1.4b.  
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Dopamine and Glutamate Interactions 
A dysfunctional interaction between the dopamine and glutamate systems 
has been implicated in numerous neuropsychiatric disorders including 
schizophrenia, Parkinson’s disease, Alzheimer’s disease, mood disorders, 
attention-deficit/hyperactivity disorder, and drug addiction (Brambilla, Perez et al. 
2003, Moghaddam and Javitt 2012, Lesch, Merker et al. 2013, Paula-Lima, Brito-
Moreira et al. 2013, Poletti and Bonuccelli 2013, Quintero 2013). The regions most 
often linked to these disorders and the dopamine-glutamate dysfunction include 
the PFC and striatum, as these regions both receive heavy innervation from the 
dopaminergic midbrain region (SN/VTA) as well as the thalamus and other 
glutamate rich regions, as described in the previous section. The PFC has been 
found to be heavily involved with behavior and attention in both humans and 
rodents, inhibiting inappropriate responses and sustaining attention over long 
delays (Goldman-Rakic 1996, Goldman-Rakic 1996, McCarthy, Puce et al. 1996, 
Robbins 1996, Robbins 2000, Khan, Koulen et al. 2001, Perry, Joseph et al. 2011). 
The striatum is involved with decision-making, sensorimotor and cognitive 
processes, goal-directed and habit learning, as well as spatial domains and motor 
activity (Brasted, Humby et al. 1997, Balleine, Delgado et al. 2007, Dunnett and 
Lelos 2010). Finally, the NA core (sometimes referred to as the ventral striatum) 
plays a role in appetitive and aversive motivational processes in both humans and 
rodents (Salamone 1994, Salamone, Cousins et al. 1994, Salamone and Correa 
2012, Segovia, Correa et al. 2012, Salamone and Correa 2013). 
Studies of signaling interactions between the dopaminergic and 
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glutamatergic systems demonstrate that the NMDA receptor is crucial in activating 
the dopamine neurons in the VTA/SN (Martinez-Fong, Rosales et al. 1992, 
Warton, Howells et al. 2009). Also, it has been found that stimulation of the D2-
class dopamine receptor is involved in the downstream inhibition of the NMDA 
receptor, weakening the excitatory response to those neurons (Kotecha, Oak et al. 
2002). Likewise, it was found that activation of D4 receptors depressed AMPA 
receptor-mediated excitatory synaptic transmission in PFC pyramidal neurons, 
which was accompanied by a D4-induced decrease of AMPA receptors at the 
synapse (Yuen, Liu et al. 2010).  
ADHD is associated with a D4 polymorphism that has been found to weaken 
D4 function (Van Tol, Wu et al. 1992, LaHoste, Swanson et al. 1996, Rowe, Stever 
et al. 1998, Thapar 1998, Thapar, O'Donovan et al. 2005). The function of D4 
receptors has been found to play a role in hyperactivity and impulsivity in adolescent 
aged mice (Avale, Falzone et al. 2004). In the rodent, D4 is located primarily in the 
prefrontal cortex (Wedzony, Chocyk et al. 2000) where the stimulation of D4 by 
dopamine exerts regulation on CaMKII (Gu and Yan 2004, Gu, Jiang et al. 2006). 
CaMKII then in turn acts on intracellular stores of the AMPA receptor (Barria, Muller 
et al. 1997, Hayashi, Shi et al. 2000). CaMKII phosphorylates the AMPA receptor 
at the P2 serine 831 site, which increases channel conductance of the GluA1 
subunit (Benke, Luthi et al. 1998). AMPA receptor activation then allows Ca2+ entry 
via removal of NMDAR Mg2+ block (Malenka and Nicoll 1999). These results 
provide substantial evidence that the dopamine and glutamate systems work in 
tandem to create a balance of neurotransmission in these regions, and in the 
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ADHD brain, these systems likely malfunction. 
The hypodopaminergic theory of ADHD asserts that the hyperactive and 
inattentive behaviors are caused by depleted levels of dopamine. Decreased 
dopamine released in the striatum and PFC would then be expected to lead to 
more active NMDA and AMPA receptors based on the studies mentioned above 
resulting in increased glutamatergic output to the striatum and SN/VTA, as well as 
an increased glutamate signal to the prefrontal cortex. Glutamate coming into the 
SN/VTA would normally go on to release more dopamine (Warton, Howells et al. 
2009); however, in the ADHD brain, this feedback does not seem to occur. 
 
Translational Neuropharmacology of ADHD Treatments 
Investigations into the effects of stimulant action on the dopaminergic 
system have revealed that these medications increase extracellular dopamine 
levels via numerous mechanisms. First, amphetamine has been found to increase 
dopamine through calcium-independent mechanisms, such as increased release 
of dopamine as well as blocking the uptake of dopamine through the DAT (Carboni, 
Imperato et al. 1989, Kahlig and Galli 2003). Methylphenidate (MPH), another 
stimulant medication commonly used to treat ADHD, increases dopamine levels 
by inhibiting dopamine reuptake via the DAT similarly to amphetamine (Kuczenski 
and Segal 1997, Gerasimov, Franceschi et al. 2000, Gerasimov, Franceschi et al. 
2000, Kuczenski and Segal 2001, Volkow, Wang et al. 2001, Huff and Davies 
2002, Marsteller, Gerasimov et al. 2002). Interestingly, norepinephrine levels have 
been found to be increased following MPH administration, as MPH has been 
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discovered to block the norepinephrine transporter (NET) in addition to the DAT 
(Gatley, Pan et al. 1996). MPH has been found to cause disinhibition of D2 
receptors, which are negatively coupled to cAMP, on the presynaptic dopaminergic 
neuron, and activation of D1 receptors, which are positively coupled to cAMP, on 
the postsynaptic neuron (Seeman and Madras 2002). These interactions result in 
an amplification of DA activity and improvement of attentional deficits, cognitive 
functioning, and motor hyperactivity (Volkow, Wang et al. 2001).  
Although stimulants are very effective in the treatment of ADHD, ~30% of 
children and ~50% of adults do not respond well to them (Schweitzer, Cummins et 
al. 2001). Moreover, the use of stimulants for treatment of ADHD is considered to 
be predominantly safe; however, concerns surround them because of the risk for 
cardiovascular problems, as well as amphetamine and MPH’s drug abuse liability 
(Kollins, MacDonald et al. 2001, Nissen 2006). The non-stimulant medication 
atomoxetine (ATX) has a unique niche as a treatment for ADHD compared to the 
stimulant medications because it has lower abuse liability than stimulants (Heal, 
Cheetham et al. 2009). ATX has been found to increase levels of dopamine and 
norepinephrine by selectively blocking the NET, which is also able to clear 
dopamine (Bymaster, Katner et al. 2002, Swanson, Perry et al. 2006, Newman, 
Darling et al. 2008) and is almost as effective as stimulants at assuaging ADHD 
symptoms (Michelson, Faries et al. 2001, Michelson, Adler et al. 2003, Adler, 
Spencer et al. 2005, Adler, Spencer et al. 2008). In vitro work has shown that ATX 
acts as an NMDA receptor antagonist (Ludolph, Udvardi et al. 2010), providing 
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preliminary evidence that current treatments for ADHD may have an effect on the 
glutamatergic system. 
Using proton magnetic resonance spectroscopy, it was found that children 
treated with ATX, but not MPH, had decreased levels of a marker for 
glutamate/glutamine in the PFC compared to non-treated ADHD individuals 
(Carrey, MacMaster et al. 2002), though in a separate imaging study MPH was 
able to decrease glutamate in the anterior cingulate region (Hammerness, 
Biederman et al. 2012). In the striatum, both ATX and MPH decreased the 
glutamate/glutamine marker levels by 56% compared to controls (Carrey, 
MacMaster et al. 2002). These results suggest that ATX may be regulating and 
activating prefrontal cortex neurons. However, another clinical study using a similar 
technique found that chronic long-acting MPH decreased glutamate levels in the 
PFC of children with ADHD (Wiguna, Guerrero et al. 2012). Wiguna et al. (2012) 
also discovered that MPH treatment resulted in an increase in the amount and 
functional state of neurons in the PFC, supporting that the current ADHD stimulant 
treatment MPH can activate PFC neurons. Further evidence of PFC activation 
comes from a study of brain-derived neurotropic factor (BDNF), a marker for 
neuronal plasticity. ATX was found to increase BDNF expression in the PFC; 
however, MPH had the opposite effect and reduced BDNF expression in the PFC 
(Fumagalli, Cattaneo et al. 2010), though it must be noted that this was study was 
completed in naïve rodents and may explain why these results don’t match the 
results seen in ADHD patients.  
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Several unconventional treatments for ADHD targeting the dopamine or 
glutamate systems have been proven to improve ADHD symptoms. Memantine is 
an uncompetitive NMDA receptor antagonist (Rogawski and Wenk 2003) and has 
also been found to act as a D2 receptor agonist (Seeman, Caruso et al. 2008). It 
has been approved and used as a treatment for Alzheimer’s disease; however, in 
an 8 week open-label pilot study in children with ADHD, memantine was found to 
improve ADHD symptoms (Findling, McNamara et al. 2007) (Findling et al, 2007). 
Surman et al. (2013) extended these findings to adults with ADHD in a separate 
open-label study lasting 12 weeks and found similar results, with memantine 
improving ADHD symptoms and neuropsychological performance (Surman, 
Hammerness et al. 2013). Deprenyl, an MAO-B inhibitor which stops the 
degradation of dopamine, is used as a treatment in Parkinson’s disease, and was 
found to alleviate ADHD symptoms (Jankovic 1993, Feigin, Kurlan et al. 1996). 
These clinical data using glutamate and dopamine altering drugs provide strong 
links for dysfunctional dopamine-glutamate interactions in ADHD, though the 
importance of this dysfunction is still unknown. Based on these data, we believe 
it’s important to not overlook the role of typical dopamine-glutamate interactions, 
but to instead focus on this relationship. Animal models of ADHD provide a unique 
opportunity to investigate neurotransmitter system dysfunction as well as to 
develop novel ways to treat ADHD targeting these systems. 
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The Spontaneously Hypertensive Rat Model of ADHD 
The seminal work of Terje Sagvolden (1945-2011) has pioneered the way 
for the spontaneously hypertensive rat (SHR) to be used as a model of ADHD-C. 
The SHR has been used as an animal model for ADHD-C since the 1970’s 
because of its sustained attention deficits (Sagvolden 2000), motor impulsiveness 
(Sagvolden, Hendley et al. 1992, Sagvolden, Metzger et al. 1992, Wultz and 
Sagvolden 1992), and hyperactivity (Sagvolden 2000) with the hyperactivity 
absent in novel situations (Knardahl and Sagvolden 1979). The SHR is the most 
widely utilized animal model of ADHD (Russell 2011, Sagvolden and Johansen 
2011); however, criticism of this strain lies in using the progenitor strain, the Wistar 
Kyoto (WKY), as a control (Alsop 2007). The NIH Animal Genetic Resource stock 
of the WKY was obtained in 1971 as outbred animals from the Kyoto School of 
Medicine in Japan. These animals were distributed to laboratories (i.e. Harlan and 
Charles River) before the F20 generation, resulting in multiple strains of the WKY 
(Sagvolden, Johansen et al. 2009). Two commonly used WKY control strains, 
WKY/NCrl (Charles River) and WKY/NHsd (Harlan), display wide genetic 
divergence (Sagvolden, Dasbanerjee et al. 2008). When contacted, both 
laboratories specified that inbred animals were subjected to single nucleotide 
polymorphism panels every quarter, thus the separate WKY strains should remain 
genetically different. However, a recent manuscript disputed this when they 
discovered that the strains at each individual laboratory produced different genetic 
profiles (Zhang-James, Middleton et al. 2013). Nonetheless, current behavioral 
evidence points to the SHR/NCrl being the most accurate animal model of ADHD-
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C (Sagvolden, Russell et al. 2005, Russell 2011) and the WKY/NHsd serves as 
the most appropriate control strain. The WKY/NCrl strain is best suited as a model 
of ADHD-PI because of its behavioral and neurochemical abnormalities 
(Sagvolden, Dasbanerjee et al. 2008, Sagvolden, Johansen et al. 2009, Roessner, 
Sagvolden et al. 2010). It has been suggested that the outbred Sprague Dawley 
(SD) rat strain, used by some groups in the past, could be used as an additional 
control (Drolet, Proulx et al. 2002, Sagvolden, Johansen et al. 2009). Taken 
together, the SHR/NCrl and WKY/NCrl models of ADHD and their control strains, 
the inbred WKY/NHsd and outbred SD, seem to be valuable translational animal 
models to assess the neurobiological dysfunction associated with ADHD. 
 
Measuring Neurotransmitters In Vivo 
Recent studies point to the importance of a dysfunctional relationship 
between dopamine and glutamate neurotransmission in ADHD, therefore new 
investigations into this relationship are necessary to improve our understanding 
and may lead to improved therapeutics for ADHD. Based on the development of 
novel and revolutionary methods of measuring dopamine and glutamate in vivo, 
we realize we are in a unique position to test our hypotheses that dopamine and 
glutamate regulation play a major role in the pathophysiology of ADHD. The 
development of carbon fiber microelectrodes and glutamate oxidase-coated 
microelectrode arrays (MEAs) provide improved spatial resolution, sub-second 
temporal resolution, and low limits of detection – <10 nM for dopamine (Miller, 
Pomerleau et al. 2012), <0.2 μM for glutamate (Miller, Pomerleau et al. 2014) – 
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over conventional techniques used in the past, such as microdialysis, which yields 
results only as quickly as every few minutes, missing much of the dynamic 
changes. Additionally, microdialysis varies across studies, with differing sampling 
times, flow rates, and probe sizes. The smaller size of the microelectrode probes 
used in the following studies causes decreased damage to tissue compared to 
microdialysis probes and allows for the in vivo characterization of dopamine and 
glutamate signaling closer to the synapse. Using these technologies, the 
exploration of dopamine and glutamate neurotransmission in the brain of the SHR 
model of ADHD is possible. The studies described here could potentially lead to 
the development of novel therapies for ADHD, which will be discussed in detail 
later. 
 
Portions of this chapter have been previously published in the open-access book 
chapter: 
 
Erin M. Miller, Theresa C. Thomas, Greg A. Gerhardt and Paul E. A. Glaser 
(2013). Dopamine and Glutamate Interactions in ADHD: Implications for the 
Future Neuropharmacology of ADHD, Attention Deficit Hyperactivity Disorder in 
Children and Adolescents, Dr. Somnath Banerjee (Ed.), ISBN: 978-953-51-1086-
6, InTech, DOI: 10.5772/54207. 
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Chapter One: Figures 
 
Figure 1.1 ADHD Subtype Prevalence 
ADHD combined type (ADHD-C, red) is the most prevalent subtype of ADHD 
diagnosed, followed by ADHD predominantly inattentive type (ADHD-PI, blue). 
ADHD hyperactive-impulsive type (ADHD-HI, green) is the least common type of 
ADHD diagnosed. 
 
 
 
 
 
 
 
 
 
 
 
Subtype Prevalence
ADHD-PI
ADHD-HI
ADHD-C
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Figure 1.2 The Dopamine Bell Curve and ADHD 
Low levels of dopamine are thought to cause decreased performance (blue arrow) 
in ADHD. The red box signifies normal levels of dopamine, causing peak 
performance. Elevation of dopamine above normal, such as in drug abuse, 
decreases performance. Modified from (Yerkes and Dodson 1908). 
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Figure 1.3 Neurotransmitter Connections in Brain Regions of Interest 
Modulatory dopaminergic neurons (blue) project to the dorsal striatum via the 
substantia nigra (SN, A9) and the ventral striatum and prefrontal cortex (PFC) via 
the ventral tegmental area (VTA, A10) in the rodent brain. From the striatum, 
inhibitory GABA neurons (red) extend to multiple regions including the thalamus, 
which has reciprocal excitatory glutamate connections (green) to the striatum, as 
well as connections to the PFC. Prefrontal cortical efferent excitatory glutamate 
neurons extend to the striatum, nucleus accumbens (NA), SN, as well as the VTA 
(Miller, Thomas et al. 2013). 
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Figure 1.4 Dopaminergic and Glutamatergic Synapses in the PFC 
A) Presynaptically, dopamine is transported into vesicles, which release their 
contents upon increase of the Ca2+ concentration. Synaptic dopamine is then able 
to stimulate dopamine receptors on both the pre- and postsynaptic neurons before 
it is cleared by the DAT or metabolism. B) Presynaptically, glutamate is stored in 
vesicles and then released into the extracellular space. Synaptic glutamate is then 
able to stimulate glutamate receptors (here represented as the NMDA and mGluR) 
on both the pre- and postsynaptic neurons before it is cleared by the EAAT located 
on nearby glial cells (Miller, Thomas et al. 2013). 
 
 
 
 
 
A) B) 
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Thesis Outline 
In these studies, dysfunctional neurotransmission was examined in a rodent 
model of attention-deficit/hyperactivity disorder (ADHD). Many children, 
adolescents, and adults do not respond well to medications currently on the market 
or the side effects are too much to handle and research suggests that novel 
therapies would benefit these individuals. Most current medications for ADHD on 
the market target the catecholamine system. Thus, in Chapter Two, the vesicular 
release and uptake of dopamine, a modulatory catecholamine neurotransmitter 
present in brain regions implicated in ADHD, were investigated in an adolescent-
aged rodent model of ADHD, the spontaneously hypertensive rat (SHR). 
Dysfunctional dopamine signaling was observed in the SHR compared to control, 
specifically the model of ADHD was found to have faster dopamine uptake in the 
ventral striatum, nucleus accumbens core, and regions within the frontal cortex 
compared to the control strain. 
By the time Chapter Two had been completed, clinical research in ADHD 
had begun implicating glutamate in the etiology of the disorder. Because of this, 
Chapter Three focused on characterizing glutamate signaling in the same method 
dopamine was characterized from Chapter Two. Vesicular release and the uptake 
of glutamate were found to be aberrant in the striatum and the frontal cortex of the 
SHR model of ADHD compared to control. Additionally, tonic levels were found to 
be overall higher in the SHR. 
 As Chapter Three came to its conclusion, novel technology became 
available that allowed for the recording of multiple sub-regions along the dorsal-
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ventral axis in the same animal in an awake, freely-moving paradigm, something 
which had never been accomplished before. This allowed the glutamate recordings 
to proceed as the animal was awake and freely-moving, instead of being 
anesthetized during the recording, as had been done in Chapters Two and Three. 
Because the SHR is a model of ADHD, the following was tested in Chapter Four: 
the hyperactive behaviors of this model of ADHD would link to the tonic and phasic 
glutamate signaling in the frontal cortex of the SHR. Moreover, methylphenidate, a 
commonly prescribed ADHD treatment, would have an effect on these tonic and 
phasic glutamate levels. Recordings were completed in the cingulate, prelimbic, 
infralimbic and dorsal peduncle cortices within the frontal cortex. However, because 
of the novelty of this technology, revisions in the electrodes used to measure 
neurotransmission in multiple brain regions became necessary. Chapter Five then 
evolved to use microelectrode arrays that had previously been used to characterize 
glutamate signaling in Chapter Three, though modified to allow for chronic freely-
moving recordings. The purpose of this final chapter was to examine the acute, 
intermediate and chronic effects of methylphenidate on tonic and phasic glutamate 
signaling within the prelimbic region of the frontal cortex in the model of ADHD and 
the control WKY strain compared to saline treatment. 
 Finally, Chapter Six works to link all of the above data into a final conclusion 
and summation. The findings from these studies are discussed and the implications 
and future directions of this research are suggested. 
 
Copyright © Erin Michelle Miller 2014 
23 
Chapter Two: The Spontaneously Hypertensive and Wistar Kyoto Rat 
Models of ADHD Exhibit Sub-Regional Differences in Dopamine Release 
and Uptake in the Striatum, Nucleus Accumbens, and Prefrontal Cortex 
 
Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is characterized by 
impulsivity, hyperactivity, inattention and cognitive impairment. The DSM-IV-TR 
classifies ADHD into 3 subtypes: predominantly inattentive type (ADHD-PI), 
predominantly hyperactive-impulsive type (ADHD-HI) and the most common 
subtype – combined (ADHD-C). The seminal work of Terje Sagvolden (1945-2011) 
has pioneered the way for the spontaneously hypertensive rat (SHR) to be used 
as a model of ADHD-C. Sagvolden and colleagues found sustained attention 
deficits (Sagvolden 2000), motor impulsivity (Sagvolden, Metzger et al. 1992, 
Wultz and Sagvolden 1992), and hyperactivity (Knardahl and Sagvolden 1979, 
Sagvolden 2000) in the SHR.  The SHR is the most widely utilized animal model 
of ADHD (Russell 2011, Sagvolden and Johansen 2011); however, criticism of this 
strain lies in using the progenitor strain, the Wistar Kyoto (WKY), as a control 
(Alsop 2007). The NIH Animal Genetic Resource stock of the WKY was obtained 
in 1971 as outbred animals from the Kyoto School of Medicine in Japan. These 
animals were distributed to laboratories (i.e. Harlan and Charles River) before the 
F20 generation, resulting in multiple strains of the WKY (Sagvolden, Johansen et 
al. 2009). Two commonly used WKY control strains, WKY/NCrl (Charles River) 
and WKY/NHsd (Harlan), display wide genetic divergence (Sagvolden, 
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Dasbanerjee et al. 2008). When contacted, both laboratories specified that inbred 
animals were subjected to single nucleotide polymorphism panels every quarter, 
thus the separate WKY strains should remain genetically different. Current 
behavioral evidence points to the SHR/NCrl being the most accurate animal model 
of ADHD-C (Sagvolden, Russell et al. 2005, Russell 2011) and the WKY/NHsd 
serves as the most appropriate control strain. The WKY/NCrl strain is best suited 
as a model of ADHD-PI because of its behavioral and neurochemical abnormalities 
(Sagvolden, Dasbanerjee et al. 2008, Sagvolden, Johansen et al. 2009, Roessner, 
Sagvolden et al. 2010). It has been suggested that the outbred Sprague Dawley 
(SD) rat strain, used by some groups in the past, could be used as an additional 
control (Drolet, Proulx et al. 2002, Sagvolden, Johansen et al. 2009). Taken 
together, the SHR/NCrl and WKY/NCrl models of ADHD and their control strains, 
the inbred WKY/NHsd and outbred SD, seem to be valuable translational animal 
models to assess the neurobiological dysfunction associated with ADHD. 
ADHD is thought to be caused by catecholamine dysfunction (Levy 1991, 
Solanto, Arnsten et al. 2001) in brain regions involved with attention and reward 
including the nucleus accumbens (NA) (Russell 2000, Podet, Lee et al. 2010) and 
striatum (Str) (Krause, Dresel et al. 2003). Prior studies examining dopamine (DA) 
function in the SHR and WKY rat brains are equivocal and have been shown to 
range from no differences (Versteeg, Van Der Gugten et al. 1976, Ferguson, 
Gough et al. 2003) to lower DA levels in the Str in vitro and in vivo in the SHR 
(Linthorst, Van den Buuse et al. 1990, Linthorst, De Lang et al. 1991). Furthermore, 
a recent microdialysis study comparing the SHR to the SD determined that the 
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SHR has 78% higher basal efflux of DA in the Str (Heal, Smith et al. 2008). Striatal 
uptake of DA in the SHR has been reported to be slower (Myers, Whittemore et al. 
1981, Leo, Sorrentino et al. 2003) or not different (Linthorst, Van den Buuse et al. 
1990, Li, Lu et al. 2007) versus the WKY, yet a higher concentration of DA 
transporters (DAT) in the Str of the SHR was found (Watanabe, Fujita et al. 1997, 
Roessner, Sagvolden et al. 2010). Additionally, it has been demonstrated that 
extracellular DA levels in the NA are higher in the SHR compared to the WKY 
(Carboni, Silvagni et al. 2003). The PFC of the SHR has been reported to have 
decreased dopamine uptake (Myers, Whittemore et al. 1981), yet a study found no 
differences in the levels of DAT, tyrosine hydroxylase, D1, D2, D3, D5 receptors, 
and dopamine-β-hydroxylase between the SHR and its progenitor strain, the WKY, 
in the PFC. Regional differences in the D4 receptors in the PFC were found, 
providing evidence that the SHR’s D4 levels are lower than those of the WKY (Li, 
Lu et al. 2007). Further, it was found that PFC AMPA receptor activity was 
increased in the SHR (Russell 2001) and inhibitory dopaminergic activity was 
found to be decreased while noradrenergic activity increased in the SHR (Russell 
2002). These findings all convey a message that dopamine regulation is 
dysfunctional in the PFC of the SHR model of ADHD; however, direct observation 
of in vivo dopamine dynamics in the separate PFC sub-regions (cingulate, 
prelimbic, and infralimbic) of the SHR have not yet been accurately defined. Thus, 
there still remains controversy surrounding the regulation of DA release and uptake 
in the SHR. 
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One of the issues with the previously described studies is that the strains of 
the SHRs and WKYs were not properly defined, as the importance of the lineage 
of these strains was not yet understood. There might also be an issue with 
comparing these studies, as the techniques used to study DA regulation ranged 
from in vitro superfusion of brain slices to in vivo microdialysis. Microdialysis has 
been the dominant technique for in vivo measures in the SHR; however, this 
methodology varies across studies, with differing sampling times, flow rates, and 
probe sizes. Therefore, comparisons from prior studies can be compromised due 
to a variety of experimental variables. Furthermore, it has been shown that the 
microdialysis probes can cause extensive damage to the surrounding tissues 
(Clapp-Lilly, Roberts et al. 1999, Rutherford, Pomerleau et al. 2007), which can 
greatly affect neurotransmitter function. Recently, it was discovered that 
microdialysis probes significantly alter presynaptic dopaminergic dynamics in the 
rodent striatum (Wang and Michael 2012). Because of this, specialized techniques 
have been developed to evaluate DA dynamics in addition to microdialysis. These 
include electrochemical techniques such as fast-scan cyclic voltammetry, constant 
potential amperometry, and high-speed chronoamperometry (Lee, Blaha et al. 
2006, Park, Takmakov et al. 2011, Zhang, Heien et al. 2011, Littrell, Pomerleau et 
al. 2012). Fast-scan cyclic voltammetry allows for high chemical and spatial 
resolution (Robinson, Venton et al. 2003, Owesson-White, Roitman et al. 2012, 
Owesson-White, Roitman et al. 2012), but it has rarely been used to map 
dopaminergic nerve terminal density profiles in discrete brain regions in vivo 
(Chadchankar and Yavich 2011, Zhang, Heien et al. 2011). Also, this technique 
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has rarely been used in conjunction with local application of chemicals from 
micropipettes placed adjacent to the microelectrodes in order to map the density 
of DA uptake and release from nerve terminals in a given brain area (Bergstrom, 
Sanberg et al. 2011, Howard, Keefe et al. 2011, Park, Takmakov et al. 2011, 
Owesson-White, Roitman et al. 2012, Sugam, Day et al. 2012, Wang and Michael 
2012). Constant potential amperometry has exceptional temporal and spatial 
resolution but is incapable of identifying the predominant contributors to the 
electrochemical response as with both fast-scan cyclic voltammetry and high-
speed chronoamperometry (Schonfuss, Reum et al. 2001, Lee, Blaha et al. 2006). 
Thus, researchers have begun to employ the power of high-speed 
chronoamperometry combined with local application of drugs from micropipettes 
to map the in vivo dynamics of release and uptake of dopamine in multiple sub-
regions within specific brain regions, such as the striatum and nucleus accumbens 
(Womersley, Hsieh et al. 2011, Littrell, Pomerleau et al. 2012). 
In this study, the use of carbon fiber microelectrodes coupled to pressure-
ejection of drugs allowed for the sub-regional mapping of DA nerve terminal 
properties with rapid temporal and spatial resolution. This technique allowed for 
better in vivo characterization of DA signaling closer to the synapse than with other 
techniques (Joyce, Glaser et al. 2007, Littrell, Pomerleau et al. 2012). In the 
present study, the information concerning the best control animals for the SHR and 
WKY models of ADHD was used to study DA release and uptake in sub-regions 
within the striatum, nucleus accumbens, and PFC to better understand dopamine 
signaling and its regulation in animal models of ADHD-C and ADHD-PI. 
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Methods 
Animal Preparation for Acute Electrochemical Recordings 
Male, 8-10 weeks old, spontaneously hypertensive rats (SHR/NCrl, average 
225 g, average PND 60), Wistar Kyoto rats (WKY/NCrl, average 210 g, average 
PND 61), and Sprague Dawley rats (SD/NCrl, average 289 g, average PND 69) 
were obtained from Charles River Laboratories (NCrl), Wilmington, 
Massachusetts. A second group of Wistar Kyoto rats (WKY/NHsd, average 202 g, 
average PND 62) was obtained from Harlan Laboratories (NHsd), Indianapolis, 
Indiana. Animals were given access to food and water ad libitum and housed in a 
12 hour light/dark cycle. Rats were anesthetized intraperitonealy (i.p.) using a 25% 
urethane solution (1.25 g/kg) and placed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, California). A circulating heating pad (Gaymar Industries, 
Inc., Orchard Park, New York) was used to maintain body temperature. The skull 
overlying the striatum was removed bilaterally for recordings in the striatum (Str, 
AP +1.0, ML ±2.5, DV -4.0 to -6.5 in 0.5 mm increments) and the nucleus 
accumbens core (NAc, AP +1.0, ML ±2.5, DV -7.0 to -7.5 in 0.5 mm increments), 
and the prefrontal cortex (AP +3.2, ML ±1.0, DV -2 to -6 in 0.5 mm increments)  – 
see Figure 2.2A (Paxinos and Watson 2009). A small hole remote from the site of 
surgery was drilled for placement of the miniature Ag/AgCl reference electrode. 
Protocols for animal use were approved by the Institutional Animal Care and Use 
Committee, which is Association for Assessment and Accreditation of Laboratory 
Animal Care International approved. All procedures were carried out in accordance 
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with the National Institutes of Health Guide for Care and Use of Laboratory Animals 
and all efforts were made to minimize animal suffering and to reduce the number 
of animals used. 
 
High-Speed Chronoamperometric Recordings of DA Release and Uptake 
High-speed chronoamperometric measurements (1 Hz sampling rate, 200 
ms total) were performed using the FAST16mkII recording system (Fast Analytical 
Sensing Technology, Quanteon, LLC, Nicholasville, Kentucky) as described 
previously (Gerhardt and Hoffman 2001, Littrell, Pomerleau et al. 2012). Single 
carbon fiber electrodes (SF1A; 30 µm outer diameter × 150 µm length; Quanteon, 
LLC, Nicholasville, Kentucky) were coated with Nafion® (5% solution, 1–3 coats at 
180oC, Aldrich Chemical Co., Milwaukee, Wisconsin) prior to an in vitro calibration 
used to determine selectivity, limit of detection, and slope before use in vivo 
(Gerhardt and Hoffman 2001). The average selectivity for all microelectrodes used 
in these experiments was 1877 ± 664 µM for DA vs. ascorbic acid. The average 
limit of detection for the measurement of DA was 0.028 ± 0.008 µM (S/N of 3). The 
average slope for the electrodes was -0.492 ± 0.111 nA/µM DA. The average 
red/ox ratio measured during the peak response of the potassium-evoked DA 
signals was 0.51 ± 0.11, which is indicative of the detection of predominantly DA 
(Gerhardt and Hoffman 2001, Joyce, Glaser et al. 2007, Littrell, Pomerleau et al. 
2012). Finally, miniature Ag/AgCl reference electrodes were prepared as 
previously described (Littrell, Pomerleau et al. 2012). 
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In Vivo Experimental Protocol 
The carbon fiber microelectrode was affixed to a micropipette (10 µm inner 
diameter) which was positioned approximately 200 µm from the carbon fiber 
electrode tip using sticky wax (Kerr USA, Romulus, Michigan). The micropipette 
was filled with filtered isotonic KCl (120 mM KCl, 29 mM NaCl, 2.5 mM 
CaCl2·2H2O) solution (pH 7.2-7.4) using a 4 inch filling needle (Cadence Inc., 
Staunton, Virginia) and a 5 ml syringe (Figure 2.1). Experiments were initiated with 
the insertion of the micropipette/microelectrode assembly into a stereotactically 
selected region of the left or right hemisphere’s Str. The system was allowed to 
reach a stable baseline dorsal to the first recording site. The 
micropipette/microelectrode assembly was then lowered to the target recording 
depth where the signal was again allowed to stabilize for an average of 5 minutes 
before the effect of a single local application of KCl on DA release was determined 
(Joyce, Glaser et al. 2007, Lundblad, af Bjerken et al. 2009, Thomas, Grandy et 
al. 2009, Morris, Bomhoff et al. 2011, Nevalainen, Af Bjerken et al. 2011). The 
potassium solution was locally applied by pressure ejection (5–25 psi for 0.5 
seconds). A single application of a set volume of KCl (75–125 nl) was delivered to 
each sub-region and was measured by determining the amount of fluid ejected 
from the micropipette using a dissection microscope fitted with an eyepiece reticule 
that was calibrated so that 1 mm of movement was equivalent to 25 nl of fluid 
ejected (Cass, Gerhardt et al. 1992, Friedemann and Gerhardt 1992). If the volume 
was determined to be greater than or less than 75-125 nl, then that data point was 
excluded. After the Str and NAc were characterized, the whole assembly was 
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removed from the brain and reinserted into the same hemisphere’s PFC using the 
same experimental procedure. 
After the KCl studies, the micropipette/microelectrode assembly was filled 
with filtered isotonic 200 µM DA solution containing 100 µM ascorbic acid (an anti-
oxidant) in 0.9% saline (pH 7.2-7.4). The micropipette/microelectrode assembly 
was then inserted stereotactically into the contralateral Str. Again, once a stable 
baseline was achieved in a location dorsal to the first recording site, the 
micropipette/microelectrode assembly was lowered to the target recording depth 
where the signal was again allowed to stabilize for an average of 5 minutes before 
the DA solution was locally applied by pressure ejection (10-30 psi for 0.5-10 s) to 
achieve a maximum amplitude ranging from 0.5 to 1.0 µM DA (Littrell, Pomerleau 
et al. 2012). The maximum concentration of the DA in the extracellular space was 
measured by subtracting the apex of the recorded peak from the baseline recorded 
prior to the ejection. If the peak amplitude was greater than or less than 0.5 to 1.0 
µM DA, then that data point was excluded. After the Str and NAc were 
characterized, the assembly was removed from the brain and reinserted into the 
same hemisphere’s PFC using the same experimental procedure as previously 
described. 
 
Materials 
Urethane, dopamine, ascorbic acid, sodium chloride, potassium chloride, 
calcium chloride and Nafion® were obtained from Sigma (St. Louis, MO). Carbon 
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fiber microelectrodes (SF1A’s) were fabricated by the Center for Microelectrode 
Technology.  
 
Histology 
Brains were removed and processed (frozen) for histological evaluation of 
microelectrode recording tracks. Only data from histologically confirmed 
placement of microelectrodes into the Str, NAc, and PFC were used for final data 
analysis. Based on histological analyses, no animals were excluded due to 
microelectrode placement errors (see Figure 2.2A). 
 
Data Analyses 
Collected data were processed using a custom Matlab®-based analysis 
package. For the potassium-evoked DA release portion of the study, maximum 
amplitude of the evoked DA peak was used as the major analysis parameter, with 
the volume of a single ejection of the KCl and the red/ox ratio – used to confirm 
the detection of DA by the Nafion®-coated microelectrodes – represented in Table 
2.1. The volume of KCl applied was kept constant across depths and strains (75–
125 nl). For DA uptake studies, the primary parameters used were the time to 80% 
decay of the DA signal (T80) and the first order rate constant of the signal (k-1), as 
well as the amount of time it took to reach the peak amplitude (Trise) – see Table 
2.2. DA signals were amplitude matched (ranging from 0.5 to 1.0 µM DA) to ensure 
accurate measurement of DA uptake kinetics (Littrell, Pomerleau et al. 2012). All 
data were averaged to one point per sub-region of the Str (dorsal, intermediate, 
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and ventral) and the NAc – see Figure 2.2A. For a graphic representation of all 
parameters, see Figure 2.2B. Outliers were excluded via the Grubb’s test before 
averaging if the conditions for homogeneity of variance were met. To compare KCl-
evoked DA release in the separate ADHD models to the control strains, as well as 
DA uptake, two-way repeated measures ANOVAs followed by Bonferroni post-hoc 
comparisons were used. Significance was set at p<0.05 (GraphPad Prism 5.0). 
 
Results 
Evoked Dopamine Release in the Striatum and NA Core 
High-speed chronoamperometry coupled with carbon fiber microelectrodes 
was used to evaluate KCl-evoked DA release because of its capability to record 
DA release within sub-regions of the Str and the NAc (Littrell, Pomerleau et al. 
2012) using a local application of 75-125 nl KCl applied in 500 µm increments 
along the dorso-ventral axis. A two-way repeated measures ANOVA revealed a 
significant effect of depth (F3,27=33.03, p<0.0001) and interaction between strain 
and depth (F9,81=2.04, p<0.05) in the peak amplitude of KCl-evoked DA release. 
Bonferroni post-hoc comparisons revealed that the SHR model of ADHD-C (n=8) 
displayed significantly decreased KCl-evoked DA release versus the WKY model 
of ADHD-PI (n=8) in the dorsal Str (Figure 2.3A, 2.3B: p<0.01). Differences in KCl-
evoked DA release were also observed between the control SD (n=7) and WKY 
model of ADHD-PI in the dorsal Str (Figure 2.3A, 2.3B: p<0.01), and the control 
SD and control WKY (n=8) strains in the intermediate region of the Str (Figure 
2.3A, 2.3C: p<0.05). There were no significant differences in volumes applied 
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between strains. In addition, there were no significant differences in the red/ox 
ratios (usually 0.4-0.6) throughout the Str and NAc in all strains, supporting the 
detection of predominantly DA in all sub-regions (Gerhardt and Hoffman 2001, 
Joyce, Glaser et al. 2007, Littrell, Pomerleau et al. 2012) – see Table 2.1. It should 
be noted that the amplitudes of the KCl-evoked signals decreased as the electrode 
moved ventrally in all strains, consistent with previous reports that the ventral Str 
has reduced vesicular-released concentrations of DA when compared to the dorsal 
Str (Gerhardt, Rose et al. 1986). 
 
Dopamine Uptake in the Striatum and NA Core 
Local applications of exogenous DA were applied in the separate strains to 
study the functional properties of the dopamine transporter (Littrell, Pomerleau et 
al. 2012). A two-way repeated measures ANOVA revealed a significant effect of 
depth (F3,30=7.49, p<0.001), strain (F3,30=3.93, p<0.05), and interaction between 
strain and depth (F9,90=3.16, p<0.01) in the length of time required to clear 80% of 
the locally applied exogenous DA (or T80). Bonferroni post-hoc comparisons 
revealed that the SHR model of ADHD-C (n=9) displayed significantly faster DA 
uptake in the ventral Str versus both the control WKY (n=8) (p<0.05) and control 
SD strains (Figures 2.4A, 2.4B: p<0.01). The SHR model of ADHD-C also 
displayed significantly faster uptake in the NAc versus both the control WKY 
(p<0.01) and control SD (Figure 2.4A, 2.4C: p<0.001). The WKY model of ADHD-
PI was found to exhibit significantly faster DA uptake in the NAc versus the control 
SD (Figure 2.4A, 2.4C: p<0.001). In the control strains, the time to clear the locally 
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applied exogenous DA was slower in the NAc when compared to the dorsal Str, 
supporting previous data that in the rodent, the NAc has lower concentrations of 
the dopamine transporter and therefore slower DA uptake rates (Cass, Gerhardt 
et al. 1992, Cass, Gerhardt et al. 1993, Cass, Zahniser et al. 1993, Calipari, 
Huggins et al. 2012, Mitch Taylor, Jaquins-Gerstl et al. 2012). Interestingly, the 
rodent models of ADHD did not display a dorsal-ventral change in dopamine 
uptake. There were no differences between the maximum amplitude achieved nor 
were there any differences in the k-1 values. Finally, there were no differences in 
the time required to reach peak amplitude (Trise) between the models of ADHD and 
control strains – see Table 2.2. 
 
Prefrontal Cortex 
High-speed chronoamperometry coupled with carbon fiber microelectrodes 
was used to evaluate KCl-evoked DA release because of its capability to record 
DA release within sub-regions of the striatum and the NAc (Littrell, Pomerleau et 
al. 2012, Miller, Pomerleau et al. 2012) using a local application of 75-125 nl KCl 
applied in 500 μm increments. To examine potential differences in evoked 
dopamine release in the separate sub-regions of the PFC between the outbred 
SD, the WKY progenitor, and the SHR model of ADHD, one-way ANOVAs were 
used. No significant differences were found between strains (cingulate cortex, 
p=0.1295; prelimbic cortex, p=0.1998; infralimbic cortex, p=0.1050). These data 
suggest that the cingulate, prelimbic and infralimbic regions in all three strains have 
a similar capacity to release dopamine during an action potential event. It’s 
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important to note that in both the SD and SHR strains, dopamine peak amplitudes 
increased as the microelectrode was moved ventrally; however, the WKY strain 
displayed the opposite effect. See Figure 2.5. Note that all dopamine signals were 
indicative of the detection of dopamine and/or norepinephrine based on the 
reduction/oxidation rations of the signals that averaged ~0.8-1.0 for all recordings. 
To examine differences in dopamine uptake in the separate prefrontal 
cortical sub-regions, we used local applications of dopamine to directly observe 
the functional properties of the dopamine and norepinephrine transporters – see 
Figure 2.6. One-way ANOVAs followed by Bonferroni post-hoc comparisons were 
used in each sub-region. It was discovered that the SHR model of ADHD (p<0.05) 
and the outbred SD control strain (p<0.001) displayed significantly faster dopamine 
uptake compared to the WKY strain in the cingulate cortex (F(2,23)=11.11). The 
average dopamine uptake times in the cingulate cortex were: SD, 30.8 ± 2 
seconds; WKY, 79.1 ± 10 seconds; and SHR, 44.8 ± 3 seconds. No dopamine 
uptake differences were observed in the prelimbic cortex (p=0.9605); however, the 
SHR exhibited significantly faster dopamine uptake compared to both the SD 
control (p<0.01) and the WKY strain (p<0.05) in the infralimbic cortex (F(2,28)=6.53). 
The average dopamine uptake times in the infralimbic cortex were: SD, 61.6 ± 8 
seconds; WKY, 49.8 ± 11 seconds; and SHR, 18 ± 4 seconds. These data reveal 
that the dopamine and norepinephrine transporters clear dopamine faster in the 
SHR in the cingulate and infralimbic cortices compared to control, but not the 
prelimbic cortex. It’s important to note that as the microelectrode was moved 
ventrally in the control SD strain, the dopamine uptake became slower; however, 
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in the WKY and SHR strains, dopamine uptake became faster as the electrode 
moved ventrally 
 
Discussion 
Striatum and NA Core 
The SHR has been used for decades as a model of ADHD because of its 
various behavioral phenotypes that mimic the symptoms of ADHD. Its progenitor 
strain, the WKY, has been used as a control for the SHR in the past with no regard 
for where the strain originated. Recent evaluations of this control strain have 
revealed that not all WKY strains are identical, genetically or behaviorally. The NIH 
stock of the WKY strain was obtained in 1971 as outbred animals from the Kyoto 
School of Medicine. These animals were distributed to laboratories such as Harlan 
and Charles River before the F20 generation, which is considered to be the gold 
standard in obtaining a pure inbred animal (Sagvolden, Johansen et al. 2009). It 
has recently been shown that two commonly used WKY strains, the WKY/NCrl 
from Charles River Laboratories and the WKY/NHsd from Harlan Laboratories, 
display wide genetic divergence (Sagvolden, Dasbanerjee et al. 2008). When 
Harlan and Charles River Laboratories were contacted, both specified that all of 
their inbred animals, both at the USA and international laboratories, were 
subjected to single nucleotide polymorphism panels every quarter, thus these 
strains from the different laboratories will remain genetically separate. Although no 
behavioral data were gathered in this study, multiple studies have concluded that 
the WKY/NCrl from Charles River is not a valid control for the SHR due to its 
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behavioral abnormalities (i.e. inattention) and is more appropriate as a model of 
ADHD inattentive type (Drolet, Proulx et al. 2002, Sagvolden, Dasbanerjee et al. 
2008, Sagvolden, Johansen et al. 2009, Roessner, Sagvolden et al. 2010, 
Sagvolden and Johansen 2011). Terje Sagvolden (1945-2011), a leading 
researcher in the SHR/ADHD field, proposed this change and concluded that the 
most appropriate models of ADHD are the SHR/NCrl (ADHD-C) and the WKY/NCrl 
(ADHD-PI) (Sagvolden, Johansen et al. 2009, Roessner, Sagvolden et al. 2010).  
As for the most suitable control strain, Sagvolden and colleagues determined that 
the inbred WKY/NHsd strain from Harlan Laboratories, not the outbred Sprague 
Dawley (SD) (Sagvolden, Johansen et al. 2009, Sagvolden and Johansen 2011), 
was the best fit control for the models of ADHD. However, the outbred SD strain 
from Charles River (SD/NCrl) was tested in this study as a potential control 
because some researchers have supported it as a way around the WKY control 
strain confusion (Drolet, Proulx et al. 2002). Although the present study does not 
discount the many behavioral studies that have used the outbred SD as a control 
for the SHR, it does suggest that studies looking at neurochemical differences in 
ADHD should focus on the inbred WKY due to a difference observed in the evoked 
DA release parameter in the intermediate Str between these control strains. Based 
on this difference in DA regulation, this study proposes that the inbred SHR 
progenitor strain, the WKY/NHsd, is the most appropriate control for 
neurochemical investigations in the SHR. 
A major purpose of this research was to help resolve the confusion over DA 
regulation in the SHR model of ADHD-C compared to the novel WKY model of 
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ADHD-PI and the control strains by exploring DA release and uptake dynamics. 
The current experiments were performed using high-speed chronoamperometry 
coupled with Nafion®-coated carbon fiber microelectrodes. This technique has 
higher spatial and temporal resolution, decreased damage to surrounding tissue 
and samples a much smaller field of DA nerve terminals along the dorso-ventral 
axis compared to most techniques used in the past (e.g. in vivo microdialysis) 
(Joyce, Glaser et al. 2007, Littrell, Pomerleau et al. 2012) The reported 
neurochemical studies in the SHR prior to 2008 were unable to distinguish 
between sub-regions along the dorsal-ventral axis in the Str due to the size of the 
microdialysis probes; however, the technology used in this study was able to 
provide a higher resolution representation of the DA dynamics within the 
heterogeneous Str (Lindvall and Bjorklund 1974, Veening, Swanson et al. 1982, 
Gerfen, Baimbridge et al. 1987, Gerfen, Herkenham et al. 1987).  
To determine differences in DA release, a single local ejection of a set 
volume of potassium chloride was used to cause calcium-dependent vesicular 
release of DA. The results of this study reveal that the SHR model of ADHD-C 
exhibits decreased depolarization-evoked DA release in the dorsal Str versus the 
WKY model of ADHD-PI. This decrease in DA release could be due to a decrease 
in stored vesicular DA (Russell, de Villiers et al. 1998) because of a potential 
dysfunction of monoamine oxidase-B (MAO-B), an enzyme that catalyzes the 
oxidation of DA in DA-producing neurons. It was recently found that an MAO-B 
inhibitor, deprenyl, significantly improved ADHD symptoms (Jankovic 1993, Feigin, 
Kurlan et al. 1996, Mohammadi, Ghanizadeh et al. 2004, Rubinstein, Malone et al. 
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2006). Moreover, it is possible that the vesicular monoamine transporter (VMAT) 
may be dysfunctional and as a result, DA may not be efficiently transported into 
the vesicles. It has been found that a common ADHD treatment, d-amphetamine, 
causes increased VMAT trafficking to the vesicular membrane within 
monoaminergic nerve terminals ex vivo (Riddle, Hanson et al. 2007), thus 
supporting a possible role for VMAT dysfunction in ADHD.  
Previous investigations have implicated the dopamine transporter (DAT) in 
the DA dysfunction of the SHR model of ADHD-C – see Table 2.3 (Watanabe, 
Fujita et al. 1997, Leo, Sorrentino et al. 2003, Viggiano, Vallone et al. 2004, 
Roessner, Sagvolden et al. 2010, Simchon, Weizman et al. 2010). In the SHR 
brain, there have been reports of increased DAT expression (Watanabe, Fujita et 
al. 1997, Roessner, Sagvolden et al. 2010) and one likely explanation for the 
decreased DA release observed in the dorsal Str is over-abundance or over-
activity of DAT. It has been shown that clearance of DA is primarily performed by 
DAT rather than metabolism or diffusion of DA (Cass, Zahniser et al. 1993). In this 
study, potassium stimulation in the dorsal Str of the SHR produced a significantly 
smaller signal amplitude than in the WKY model of ADHD, suggesting that the DA 
was likely cleared through uptake by DAT before it reached our microelectrode. To 
the best of our knowledge, no study has been able to quantify levels of DAT in 
specific striatal sub-regions on the dorso-ventral axis; however, the ratio of DA to 
DAT to DA receptors is similar in the naïve rodent Str and NAc (Madras, Miller et 
al. 2005), supporting that DAT is the major regulator of DA neuron signaling 
strength and duration. However, when DA uptake was examined in the dorsal Str 
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sub-region by locally applying exogenous DA, no differences in DA uptake were 
observed between these strains. It is worth noting that DA uptake was not studied 
directly after the local application of KCl because KCl stimulation allows for the 
direct examination of the release capacity output of the surrounding terminals. If 
the uptake dynamics of these signals were studied, changes in uptake may not be 
seen due to the overwhelming concentrations, or ‘ceiling effect,’ of the 
neurotransmitter and this effect would mask DAT productivity. In order to fully study 
DA regulation in these strains, exogenously applied DA was used to examine 
uptake dynamics. While no differences in uptake were found in the dorsal Str, it is 
possible that exogenously applied DA may not be as efficiently removed by DAT 
as the DA released inside the synapse. In addition, KCl depolarizes the DA nerve 
terminal membrane causing synaptic release of DA, creating the possibility that 
the action potential could potentiate some of the differences observed in DA 
uptake. The DAT is known to be electrogenic and depolarization causes the DAT 
to exist in a different state than the basal state (Reith, Jacobson et al. 1991, 
Zahniser, Gerhardt et al. 1998, Hoffman, Zahniser et al. 1999, Kandasamy 2000, 
El Ayadi, Afailal et al. 2001). By testing with local applications of DA rather than by 
using depolarization alone, the current study was able to prevent the activation of 
DAT to fully focus on the uptake capability of the protein, which showed no 
differences in the SHR versus the other strains in the dorsal Str. While this KCl-
evoked difference was not observed in the other striatal sub-regions in our study, 
DAT location is not homogenous throughout the Str (Hebert et al. 1999) and the 
possibility exists that when the KCl-evoked DA is released from the nerve terminals 
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in the dorsal Str of the SHR model of ADHD-C, the DAT is the primary mechanism 
to clear the released DA. 
Interestingly, in the ventral striatum and nucleus accumbens core (NAc), it 
was discovered that the SHR model of ADHD-C demonstrated faster DA uptake 
compared to both of the control strains, both of which are areas highly implicated 
in impulsive ADHD behaviors (Basar, Sesia et al. 2010). These results may provide 
neurochemical evidence for this ADHD-like behavior observed in the SHR 
(Sagvolden, Metzger et al. 1992, Wultz and Sagvolden 1992, Sagvolden 2000, 
Johansen and Sagvolden 2004, Russell 2011). As mentioned previously, 
clearance of DA is primarily performed by DAT rather than metabolism or diffusion 
(Cass, Zahniser et al. 1993). Therefore, it is reasonable to assume that the faster 
uptake observed in the rodent model of ADHD-C is due to differences in DAT 
expression, activity, and/or affinity for dopamine. Michaelis-Menten kinetics 
dictates that two variables affect an enzyme’s productivity, affinity and velocity. 
The k-1 parameter (the first-order rate constant) is a measure of velocity and 
remained unchanged in all strains. This suggests that the affinity of DAT for DA is 
increased in the ventral Str and NAc of the rodent model of ADHD-C. Increased 
affinity of DAT for DA could be due to increased concentrations of the DAT at the 
synaptic membrane resulting from increased DAT trafficking, which, to our 
knowledge, has not been investigated in specific striatal sub-regions. Because the 
SHR has been found to possess increased DAT expression (Watanabe, Fujita et 
al. 1997, Roessner, Sagvolden et al. 2010, Wallis 2010), the results from this study 
suggest that increased DAT expression is coupled to increased DAT function at a 
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synaptic level. No strain differences were observed in depolarization-evoked DA 
release in the NAc; however, the faster DA uptake when exogenous DA was 
applied supports that the DA is cleared by an amplified number of DATs or 
enhanced DAT activity. Future studies should focus on quantifying the levels of 
DAT in the separate striatal sub-regions to obtain more precise evidence of the 
role of DAT in the rodent models of ADHD.  
Finally, in the dorsal Str, the WKY model of ADHD-PI displayed increased 
evoked DA release as well as faster DA uptake in the NAc when compared to the 
control SD strain. These findings are in agreement with a previous study which 
showed that behavioral activity in running wheels was negatively correlated with in 
vitro K+-stimulated DA release in rat NAc and dorsal Str but not in the shell division 
of the NA (Tarr, Kellaway et al. 2004).  
The present study uses a neurochemical technique to complement the 
established behavioral evidence indicating that the SHR/NCrl is a useful rodent 
model of ADHD-C. The decreased KCl-evoked DA release observed in the dorsal 
sub-region of the Str may aid in the explanation of why the SHRs express some 
behavioral aspects of ADHD, as the dorsal Str of the rat is akin to the human 
putamen (Grahn, Parkinson et al. 2008) and is believed to play a role in motor 
activity (Grahn, Parkinson et al. 2008). The results from this study reveal that the 
hyperactive SHR has DA dysfunction in this region compared to the less active 
WKY/NCrl. The findings of DA dysfunction in the ventral Str and NAc of the SHR 
is consistent with the understanding that the more ventral Str is associated with 
impulsive behaviors (Basar, Sesia et al. 2010). Finally, the NAc may play a role in 
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the inattention observed in individuals with ADHD (Volkow, Wang et al. 2009, 
Volkow, Wang et al. 2011) and the differences in DA uptake between the SHR/NCrl 
and WKY/NCrl models of ADHD and the control strains provide preliminary 
neurochemical evidence for the inattentive behavior observed in these strains; 
however, more evidence is needed to confirm the speculation that DAT is altered 
in discrete sub-regions of the Str and NAc in the SHR/NCrl and WKY/NCrl.  
 
Prefrontal Cortex 
Previous investigations have implicated the dopamine transporter (DAT) in 
the DA dysfunction of the SHR model of ADHD (Watanabe, Fujita et al. 1997, Leo, 
Sorrentino et al. 2003, Viggiano, Vallone et al. 2004, Roessner, Sagvolden et al. 
2010, Simchon, Weizman et al. 2010, Womersley, Hsieh et al. 2011) and our data 
revealing differences in dopamine regulation in the striatum can be attributed to 
increased activity of the DAT in the striatum of the SHR. It is reasonable to assume 
that if the striatum has increased DAT activity, it’s likely that similar dopamine 
dysfunction exists in the PFC of the SHR. It’s important to clarify that the 
norepinephrine transporter (NET) is present in the PFC in much greater 
concentrations than the DAT and dopamine uptake in the PFC is preferentially due 
to the NET instead of the DAT (Moron, Brockington et al. 2002), so investigations 
into the mechanism of dopamine clearance in the PFC of the SHR should be 
examined in the future. 
Using similar volumes of a potassium solution, evoked overflow of 
catecholamine nerve terminals surrounding the tip of the carbon fiber 
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microelectrode was used to attempt to locate differences in vesicular dopamine 
storage in the different PFC sub-regions. Upon stimulation, no differences were 
observed between the inbred SHR model of ADHD, the inbred progenitor WKY 
and the outbred SD control strains. The lack of differences signifies to us that the 
separate PFC sub-regions all have the same capacity to store and release 
dopamine and/or norepinephrine in these strains. MAO and VMAT, both implicated 
in ADHD, can then be considered to be functional in the PFC of the SHR model of 
ADHD and drugs targeting these proteins, such as deprenyl, may not be useful in 
this model. 
Though no differences were observed in the KCl-evoked dopamine signals, 
there were significant differences in the length of time required to clear exogenous 
dopamine applications between the SHR and control strains. Similar maximum 
dopamine amplitudes were achieved by applying various volumes of an 
exogenous dopamine solution in order to evaluate the uptake kinetics of the 
signals. The DAT is electrogenic and depolarization causes the DAT to change 
from the basal state (Reith, Jacobson et al. 1991, Zahniser, Gerhardt et al. 1998, 
Hoffman, Zahniser et al. 1999, Kandasamy 2000, El Ayadi, Afailal et al. 2001) and 
in order to test the full uptake capabilities of the transporters, including both the 
DAT and NET, it was necessary to prevent the action potentials induced with 
potassium. Utilizing this approach, it was discovered that the SHR displayed faster 
uptake in the cingulate and infralimbic cortices compared to the WKY strain, but 
not the prelimbic cortex. The SHR model of ADHD was also discovered to have 
faster dopamine uptake compared to the SD strain in the infralimbic cortex. These 
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results are significant because the cingulate cortex is involved with learning and 
memory, playing a vital role in Papez circuit and the cortical control of emotions in 
humans (Granziera, Hadjikhani et al. 2011). This data further demonstrates that 
there exists a neurochemical dysfunction in a region important for linking 
behavioral outcomes to motivation (Adey 1951, Adey and Meyer 1952) in the SHR. 
Also, the infralimbic cortex in rodents is known to be involved with attention to 
stimulus features, task contingencies, and attentional set-shifting (Dalley, Cardinal 
et al. 2004) – all behaviors known to be affected in individuals with ADHD (Krusch, 
Klorman et al. 1996, Mehta, Goodyer et al. 2004, Klimkeit, Mattingley et al. 2005).  
The SHR has previously been found to have dysfunctional dopamine 
dynamics in the striatum and NA core (Miller, Pomerleau et al. 2012), but here we 
describe evidence for faster dopamine uptake in the cingulate and infralimbic 
cortices of the medial PFC. These regions are heavily implicated in ADHD (Arnsten 
and Dudley 2005, Arnsten and Li 2005, Arnsten 2009) and this data gives further 
evidence for use of the SHR as a model of ADHD. Therapeutics targeting this 
dysfunction may prove to be useful in the SHR. However, MPH, a DAT blocker, 
has been investigated and found to not be useful in this model because instead of 
calming these animals as it does in humans, it increased locomotion in clinically 
relevant doses (Sagvolden, Metzger et al. 1992, Sagvolden 2000, Sagvolden and 
Johansen 2011). This signifies to us that targeting the NET instead of the DAT, 
such as with the use of ATX, may provide a more useful option of targeting PFC 
dopamine dysfunction in the SHR model of ADHD. 
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Conclusions 
In conclusion, the results from this study demonstrate that the SHR/NCrl 
model of ADHD-C and the WKY/NCrl model of ADHD-PI have distinct differences 
in the regulation of DA release and uptake in the Str and NAc compared to each 
other as well as compared to the WKY and SD control strains. Additionally, the 
data presented above in the SHR model of ADHD provides evidence for 
dopaminergic system dysfunction in the PFC. This study further reveals that the 
SD strain may not be a useful control when investigating neurochemical changes 
in the rodent models of ADHD. However, because of increasing evidence that 
ADHD is not limited to purely DA dysfunction, it will be valuable to study other 
neurotransmitter systems in the future, such as norepinephrine and glutamate 
(Russell 2001, Kotecha, Oak et al. 2002, Russell 2002, Madras, Miller et al. 2005, 
Heal, Smith et al. 2008), and how they relate to the SHR and WKY rodent models 
of ADHD. Glutamate regulation in the SHR may be impaired, creating the 
possibility that targeting the dopamine-glutamate interaction in this model of ADHD 
may prove useful with novel therapeutics. 
Animal models grant us the ability to investigate neurotransmitter system 
regulation in vivo, creating a more accurate depiction of the dysfunction in multiple 
sub-regions throughout the brain. Using these rodent models of ADHD, common 
ADHD treatments, such as MPH and ATX, as well as unconventional treatments, 
such as memantine and deprenyl, should be used to examine the effects of these 
drugs on the dopamine and glutamate systems with the ultimate goal of 
discovering novel ways to treat ADHD with minimal side-effects and clear long-
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term safety and efficacy. It is our belief that targeting the interaction between the 
dopamine and glutamate systems will provide an avenue not yet understood to 
achieve this goal. 
As more and more research is beginning to implicate a dysfunctional 
glutamate system in ADHD, it’s hard to ignore that glutamate may be playing some 
role in the pathophysiology of ADHD. It is thought that the relationship between the 
dopamine and glutamate systems is a likely target for future pharmacotherapies. 
It is our hope that through modification of these interactions, we will be able to 
better treat individuals with ADHD and greatly improve their quality of life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
Portions of this chapter have been previously published in the manuscript: 
Erin M. Miller, Francois Pomerleau, Peter Huettl, Vivienne A. Russell, Greg A. 
Gerhardt & Paul E.A. Glaser. 2012. The Spontaneously Hypertensive and Wistar 
Kyoto Rat Models of ADHD Exhibit Sub-Regional Differences in Dopamine Release 
and Uptake in the Striatum and Nucleus Accumbens. Neuropharmacology, 63(8): 
1327-1334. PMCID: PMC3485688. 
Permission was obtained from Elsevier for use (License No. 3303710899101). 
 
As well as the open-access book chapter: 
Erin M. Miller, Theresa C. Thomas, Greg A. Gerhardt and Paul E. A. Glaser (2013). 
Dopamine and Glutamate Interactions in ADHD: Implications for the Future 
Neuropharmacology of ADHD, Attention Deficit Hyperactivity Disorder in Children 
and Adolescents, Dr. Somnath Banerjee (Ed.), ISBN: 978-953-51-1086-6, InTech, 
DOI: 10.5772/54207. 
 
 
 
 
 
 
 
 
Copyright © Erin Michelle Miller 2014 
50 
Chapter Two: Figures 
 
Figure 2.1 Carbon Fiber Electrochemistry 
The micropipette was placed 200 µm away from the carbon fiber tip, filled with 
either KCl (for release studies) or dopamine (DA, for uptake studies). When 
dopamine (either endogenous or exogenous) came into contact with the carbon 
fiber, a voltage of +0.55 V was applied (100 ms) vs. a Ag/AgCl reference electrode, 
dopamine was oxidized into dopamine-ortho-quinone and 2 electrons were 
measured and amplified by the FAST16mkII recording system. The voltage was 
changed to 0.0 V (100 ms) vs. a Ag/AgCl reference electrode and some of the 
dopamine-ortho-quinone product was reduced back into dopamine, while some 
diffused away, resulting in a red/ox ratio. A charge exclusion layer of Nafion© 
excluded electroactive interferent molecules, such as ascorbic acid (AA). 
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Figure 2.2 Experimental Methodology 
A) Carbon fiber microelectrode placement within the rodent Str and NAc. The 
diagram on the right shows the approximate location of the tip of the carbon fiber 
microelectrode, and the left side shows the actual carbon fiber track (highlighted 
with the black box) from a 20 μm slice stained with cresyl violet. The carbon fiber 
microelectrode was lowered in 500 μm increments in both hemispheres (one 
hemisphere for KCl recordings and one for DA) and the average of these 
recordings was used to give one data point per sub-region. ac, anterior 
commissure. B) In Vivo Parameters. The arrow on the x axis indicates the time 
point of local application of KCl or DA. The KCl parameters used were the 
maximum amplitude of evoked DA release, represented by the purple dashed 
lines, and the ratio of the reduction/oxidation current (solid black line divided by the 
solid grey line). DA parameters included the time it took to clear 80% of the 
exogenous DA in reference to the maximum amplitude (T80), the curve fit based 
on first order fitting of the signal decay (k-1), and the amount of time it took to reach 
the peak amplitude (Trise), which are all represented by the orange dashed lines 
(Miller, Pomerleau et al. 2012). 
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Figure 2.3 Decreased KCl-Evoked Dopamine Release in the SHR  
The model of ADHD-C demonstrated significantly decreased KCl-evoked DA 
release versus the model of ADHD-PI in the dorsal Str (**p<0.01). The control SD 
also displayed decreased KCl-evoked DA versus the model of ADHD-PI in the 
dorsal Str (‡‡p<0.01). In the intermediate Str, it was observed that the control WKY 
displayed significantly increased KCl-evoked DA release versus the control SD 
strain (§p<0.05). Mean ± SEM. B) Representative tracing of the difference in KCl-
evoked DA release in the dorsal Str between the model of ADHD-C, the model of 
ADHD-PI, and the control SD. C) Representative tracing of the difference in KCl-
evoked DA release in the intermediate Str between the control SD and control 
WKY strains. Arrows indicate local application of KCl (Miller, Pomerleau et al. 
2012). 
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Figure 2.4 Dopamine Uptake in the SHR Model of ADHD-C, WKY Model of ADHD-
PI and Control Strains 
A) A DA uptake depth profile through the Str and NA core revealed that B) in the 
ventral Str, the model of ADHD-C displayed faster DA uptake versus both the 
control SD (xxp<0.01) and the control WKY (†p<0.05). C) In the NAc, the model of 
ADHD-C exhibited faster DA uptake versus the control SD (xxxp<0.001) and the 
control WKY (††p<0.01). The model of ADHD-PI displayed faster DA uptake versus 
the control SD (‡‡‡p<0.001) in the NAc. Arrows indicate local applications of DA. 
Mean ± SEM (Miller, Pomerleau et al. 2012). 
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Figure 2.5 KCl-Evoked Differences in the PFC 
No differences were observed between the outbred SD control strain, the WKY 
progenitor strain, and the SHR model of ADHD in the KCl-evoked dopamine peak 
amplitudes following a local application of KCl in any of the prefrontal cortical sub-
regions. Values represent the mean ± SEM (Miller, Thomas et al. 2013). 
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Figure 2.6 Dopamine Uptake in the PFC 
The SHR model of ADHD and the outbred SD control strain exhibited significantly 
faster dopamine uptake than the WKY strain in the cingulate cortex (*p<0.05, 
***p<0.001). No dopamine uptake differences were observed in the prelimbic 
cortex; however, the SHR exhibited significantly faster dopamine uptake in the 
infralimbic cortex compared to both the SD control and WKY strain (*p<0.05, 
**p<0.01). Values represent the mean ± SEM (Miller, Thomas et al. 2013). 
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Chapter Two: Tables 
Table 2.1 KCl-Evoked Dopamine Release 
 Sub-Region  
SHR/NCrl 
ADHD-C 
WKY/NCrl 
ADHD-PI 
 
WKY/NHsd 
Inbred 
Control 
SD/NCrl 
Outbred 
Control 
Red/Ox 
Dorsal Str 
Intermed Str 
Ventral Str 
NA Core 
 
0.58 ± 0.07 
0.47 ± 0.06 
0.45 ± 0.06 
0.52 ± 0.10 
0.53 ± 0.11 
0.58 ± 0.11 
0.64 ± 0.20 
0.57 ± 0.07 
 
0.47 ± 0.12 
0.51 ± 0.07 
0.55 ± 0.09 
0.51 ± 0.06 
0.50 ± 0.08 
0.65 ± 0.05 
0.62 ± 0.10 
0.66 ± 0.07 
Volume 
(nl) 
Dorsal Str 
Intermed Str 
Ventral Str 
NA Core 
92 ± 4 
92 ± 3 
92 ± 4 
97 ± 3 
89 ± 4 
94 ± 3 
94 ± 4 
94 ± 5 
95 ± 2 
93 ± 3 
95 ± 3 
98 ± 1 
94 ± 2 
93 ± 2 
93 ± 3 
95 ± 1 
Similar reduction/oxidation ratios were obtained when the KCl was applied, all 
indicative for the presence of dopamine. The volumes of KCl applied between 
strains were not significantly different (mean ± SEM). 
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Table 2.2 Dopamine Uptake 
 
Sub-
Region 
 
SHR/NCrl 
ADHD-C 
WKY/NCrl 
ADHD-PI 
 
WKY/NHsd 
Inbred 
Control 
SD/NCrl 
Outbred 
Control 
k-1 (sec-1) 
Dorsal Str 
Intermed Str 
Ventral Str 
NA Core 
 
0.007 ± 0.001 
0.011 ± 0.003 
0.010 ± 0.003 
0.008 ± 0.002 
0.009 ± 0.003 
0.009 ± 0.004 
0.009 ± 0.004 
0.008 ± 0.003 
 
0.014 ± 0.003 
0.013 ± 0.003 
0.011 ± 0.003 
0.006 ± 0.001 
0.014 ± 0.003 
0.009 ± 0.001 
0.009 ± 0.001 
0.008 ± 0.001 
Trise (sec) 
Dorsal Str 
Intermed Str 
Ventral Str 
NA Core 
7.95 ± 1.15 
5.71 ± 0.41 
6.71 ± 1.38 
9.25 ± 0.50 
7.07 ± 0.94 
7.28 ± 0.75 
7.64 ± 0.79 
9.36 ± 0.85 
7.85 ± 1.51 
8.24 ± 0.78 
9.43 ± 0.83 
12.9 ± 1.71 
7.85 ± 1.51 
8.91 ± 3.38 
10.3 ± 2.73 
12.6 ± 3.5 
Peak 
Amplitude 
(µM) 
Dorsal Str 
Intermed Str 
Ventral Str 
NA Core 
0.89 ± 0.04 
0.74 ± 0.03 
0.72 ± 0.04 
0.73 ± 0.06 
0.83 ± 0.04 
0.79 ± 0.04 
0.74 ± 0.04 
0.79 ± 0.02 
 
0.75 ± 0.04 
0.77 ± 0.04 
0.69 ± 0.03 
0.66 ± 0.04 
0.73 ± 0.04 
0.73 ± 0.02 
0.82 ± 0.03 
0.74 ± 0.03 
k-1 values and the amount of time it took to reach the peak amplitude (Trise) did not 
vary between strains. Similar amplitudes of exogenous DA were applied to the Str 
and NAc and did not significantly differ (mean ± SEM). 
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Table 2.3 Dopamine Transporter Function in the SHR 
DAT Function Study 
↑ Current 
↑ Roessner, Sagvolden et al. 2010 
↑ Watanabe, Fujita et al. 1997 
= Li, Lu et al. 2007 
= 
Linthorst, Van den Buuse et al. 
1990 
↓ Leo, Sorrentino et al. 2003 
Present and past data on dopamine transporter function in the SHR model of 
ADHD reveal conflicting results versus control, likely due to unknown strains and 
variable techniques. 
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Chapter Three: Aberrant Glutamate Signaling in the Prefrontal Cortex and 
Striatum of the Spontaneously Hypertensive Rat Model of Attention-
Deficit/Hyperactivity Disorder 
 
Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is estimated to affect 6% of 
children worldwide and a portion of those will continue to suffer into adulthood 
(Polanczyk, de Lima et al. 2007). Hyperactivity lessens in adolescence, though 
cognitive impairment persists (Brassett-Harknett and Butler 2007, Spencer, 
Biederman et al. 2007). Those diagnosed with ADHD combined type (ADHD-C), 
characterized by hyperactivity and inattention, had larger impairments including 
lower grades in school and more arrests during adolescence compared to the other 
ADHD subtypes (inattentive and hyperactive/impulsive) (Molina, Hinshaw et al. 
2009). Thus, evidence suggests the efficacy of treatments for adolescents could 
be improved and calls for a better understanding of the pathophysiology of ADHD, 
particularly for those diagnosed with ADHD-C. 
ADHD has been posited to be caused by hypofunctional catecholamine 
systems (Rastogi and Singhal 1976, Robbins and Sahakian 1979, Levy 1991, 
Solanto, Arnsten et al. 2001) in various brain regions including the nucleus 
accumbens (Russell 2000, Podet, Lee et al. 2010), striatum (Krause, Dresel et al. 
2003) and prefrontal cortex (PFC) (Halperin and Schulz 2006, Arnsten 2009). 
However, recent clinical evidence has implicated glutamate, the main excitatory 
neurotransmitter in the CNS (Danbolt 2001), in ADHD. Imaging studies of children 
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and adults with ADHD revealed increased levels of glutamate/glutamine in the 
striatum and anterior cingulate cortex of the PFC (Moore, Biederman et al. 2006, 
Moore, Biederman et al. 2007, Dramsdahl, Ersland et al. 2011). Furthermore, 
treatment with the ADHD medications methylphenidate and atomoxetine were 
found to lower these levels (Hammerness, Biederman et al. 2012). Memantine, an 
NMDA receptor antagonist, was found to improve ADHD symptoms in both 
children and adults (Findling, McNamara et al. 2007, Surman, Hammerness et al. 
2012). Together, these data provide evidence for altered glutamate regulation in 
the ADHD brain. 
Studies of signaling interactions between dopamine and glutamate 
demonstrate that stimulation of the D2-class dopamine receptor is involved in the 
downstream inhibition of the NMDA receptor, weakening the excitatory response 
(Kotecha, Oak et al. 2002). Likewise, activation of D4 dopamine receptors 
depresses AMPA receptor-mediated excitatory synaptic transmission in PFC 
pyramidal neurons, which is accompanied by a D4-induced decrease of AMPA 
receptors at the synapse (Yuen, Zhong et al. 2010). A hypodopaminergic state in 
the ADHD brain may then be expected to lead to more active NMDA/AMPA 
receptors and a subsequent increase in glutamate output. 
Behavioral studies have demonstrated that the spontaneously hypertensive 
rat (SHR) exhibits key symptomatic aspects of ADHD-C, including hyperactivity, 
inattention and impulsivity (Knardahl and Sagvolden 1979, Knardahl and 
Sagvolden 1981, Sagvolden and Johansen 2012). Previous work from our lab has 
revealed hypofunctional dopamine systems in the ventral striatum, nucleus 
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accumbens core, and PFC of the SHR compared to the Wistar Kyoto (WKY) 
control (Miller, Pomerleau et al. 2012, Miller, Thomas et al. 2013). Therefore, due 
to the current understanding of the dopamine/glutamate relationship, we 
hypothesized that a hyperglutamatergic state exists in the striatum, nucleus 
accumbens core and PFC of the SHR. Understanding glutamate signaling in the 
SHR could provide us with an opportunity to study novel therapeutics for the 
treatment of ADHD. 
 
Materials and Methods 
Animal Preparation for Acute Electrochemical Recordings 
Male, 7 week old spontaneously hypertensive rats (SHR) were obtained 
from Charles River Laboratories (NCrl), Wilmington, Massachusetts, while Wistar 
Kyoto (WKY) rats were obtained from Harlan Laboratories (NHsd), Indianapolis, 
Indiana (Sagvolden, Johansen et al. 2009). Animals were given access to food 
and water ad libitum and housed in a 12 hour light/dark cycle. All animals remained 
in a quarantine period for one week to ensure no travel-related stress confounds 
were possible. 
On the day of recording, 8 week old rats were anesthetized using a 25% 
urethane solution (1.25 g/kg i.p.) and placed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, California). A circulating heating pad (Gaymar Industries, 
Inc., Orchard Park, New York) was used to maintain body temperature. A skin 
incision was made and muscle/connective tissue were reflected. The skull 
overlying the striatum (Str) and prefrontal cortex (PFC) was removed bilaterally for 
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recordings in the Str (from bregma: AP +1.0 and ML ±2.5; from surface of the brain: 
DV -4.0 to -6.5 in 0.5 mm increments), nucleus accumbens core (NAc, from 
bregma: AP +1.0 and ML ±2.5; from the surface of the brain: DV -7.0 to -7.5 in 0.5 
mm increments), and PFC (from bregma: AP +3.2 and ML ±1.0; from surface of 
the brain: DV -2.5 to -5 in 0.5 mm increments) (Paxinos and Watson 2009) – see 
Figure 3.1d for a reference to the brain regions studied. A small hole remote from 
the site of surgery was made for placement of the miniature Ag/AgCl reference 
electrode. Protocols for animal use were approved by the Institutional Animal Care 
and Use Committee, which is Association for Assessment and Accreditation of 
Laboratory Animal Care International approved. All procedures were carried out in 
accordance with the National Institutes of Health Guide for Care and Use of 
Laboratory Animals. 
 
High-Speed Amperometric Recordings of Glutamate 
High-speed amperometric recordings, displayed at a frequency of 4 Hz, 
were performed using the FAST16mkIII recording system (Fast Analytical Sensing 
Technology, Quanteon, LLC, Nicholasville, Kentucky). Glutamate-oxidase (GluOx) 
coated microelectrode arrays (MEAs) consisting of 4 Pt sites measuring 15 x 333 
µm arranged vertically in dual pairs (S2 conformation) were used as previously 
described (Hinzman et al. 2012; Thomas et al. 2012; Hinzman et al. 2010). Briefly, 
1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), 0.125% 
glutaraldehyde (Glut; Sigma-Aldrich), and 1% glutamate oxidase (GluOx; US 
biological, Salem, MA) were prepared and coated onto the bottom pair of recording 
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sites to allow for the conversion of glutamate to α-ketoglutarate and the reporter 
molecule, H2O2. The top pair of recording sites, or the sentinel sites, only received 
a coating of the BSA/Glut matrix to allow for background measures and subtraction 
to obtain a self-referenced glutamate signal (Hinzman et al. 2010; Burmeister and 
Gerhardt 2001) – see Figures 3.1a and 3.1c. To eliminate interferent molecules 
such as ascorbic acid and dopamine from reaching the Pt sites, 1,3–
phenylenediamine (mPD), a molecular size exclusion layer, was electroplated onto 
both the GluOx and sentinel sites (Hinzman et al. 2010) – see Figure 3.1b. 
Immediately before in vivo use, an in vitro calibration, as described previously 
(Hinzman et al. 2010), was used to determine selectivity (glutamate vs. ascorbic 
acid), limit of detection (in µM, S/N=3), and sensitivity (slope, nA/µM). The average 
slope, limit of detection and selectivity for all electrodes used are presented in Table 
3.1. No significant differences in the performance of the MEAs used between 
strains were observed. 
 
In Vivo Experimental Protocol 
After calibration, a micropipette (A-M Systems, Inc., Everett, WA) was 
pulled and bumped to an inner diameter of 10 µm and placed atop and centered 
between the 4 Pt sites and positioned approximately 100 µm from the MEA surface 
using sticky wax (Kerr USA, Romulus, Michigan). The micropipette was filled with 
filtered isotonic KCl (70 mM KCl, 79 mM NaCl, and 2.5 mM CaCl2), using a 4 inch 
filling needle (Cadence Inc., Staunton, Virginia) and a 5 ml syringe. 
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Experiments were initiated with the insertion of the MEA/micropipette 
assembly into a stereotactically selected region of the left or right hemisphere’s 
Str. The system was allowed to reach a stable baseline dorsal to the first recording 
site for an average of 45 minutes. The MEA/micropipette assembly was then 
lowered to the target recording depth where the signal was again allowed to 
stabilize for five minutes before five local applications of KCl, separated by an 
average of 60 seconds each, were used to determine the effects on glutamate 
release (Hinzman, Thomas et al. 2010). Only the first three KCl-evoked peaks 
were used for data analyses because of their reproducibility (see Figure 3.2d for 
an example). The KCl solution was applied by pressure ejection (5–25 psi for 0.5 
seconds) to achieve a set volume of KCl (75–125 nl) which was measured by 
determining the amount of fluid ejected from the micropipette using a dissection 
microscope fitted with an eyepiece reticule that was calibrated so that 1 mm of 
movement was equivalent to ~25 nl of fluid ejected (Cass, Gerhardt et al. 1992, 
Friedemann and Gerhardt 1992). If the volume was determined to be greater or 
less than 75-125 nl, then that data point was excluded. Tonic glutamate levels were 
obtained by averaging the 10 seconds immediately prior to the first KCl-evoked 
glutamate peak in each sub-region. After the Str and NAc were characterized, the 
MEA/micropipette assembly was removed from the brain and reinserted into the 
same hemisphere’s PFC using the same experimental procedure. 
After the KCl and tonic glutamate studies, the micropipette was filled with 
filtered isotonic 200 µM glutamate solution in 0.9% saline (pH 7.4). The 
MEA/micropipette assembly was inserted stereotactically into the contralateral Str. 
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Again, once a stable baseline was achieved in a location dorsal to the first 
recording site, the MEA/micropipette assembly was lowered to the target recording 
depth where the signal was allowed to stabilize for an average of five minutes 
before the exogenous glutamate solution was locally applied by pressure ejection 
(8-30 psi for 0.5-10 s) to achieve a range of maximum amplitudes between 1 and 
50 µM glutamate (Hinzman, Thomas et al. 2010, Hinzman, Thomas et al. 2012). If 
the peaks obtained were less than or greater than 1 to 50 µM glutamate, then those 
data points were excluded (Hinzman, Thomas et al. 2010). After the Str and NAc 
were characterized, the MEA/micropipette assembly was removed from the brain 
and reinserted into the same hemisphere’s PFC using the same experimental 
procedure as previously described. 
 
Materials 
Urethane, L-glutamic acid, ascorbic acid, bovine serum albumin, 
gluteraldehyde, sodium chloride, potassium chloride, and calcium chloride were 
obtained from Sigma-Aldrich (St. Louis, MO). Glutamate oxidase was obtained from 
US Biological (Salem, MA). 
 
Histology 
Brains were removed and processed (frozen) for histological evaluation of 
microelectrode recording tracks. Only data from histologically confirmed 
placements of microelectrodes into the striatum, nucleus accumbens core, and 
prefrontal cortex in order to have a repeated measures design were used for final 
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data analysis. No animals were excluded due to placement errors. 
 
Data Analyses 
Collected data were processed using a custom Matlab®-based analysis 
package. Two-way repeated measures ANOVAs were used to examine differences 
between strain and depth for tonic glutamate, KCl-evoked glutamate, and 
glutamate uptake parameters followed by Bonferroni post-hoc comparisons if 
significant effects existed. Significance was set at p<0.05 (GraphPad Prism 6.0). 
 
Results 
Tonic and KCl-Evoked Glutamate Release in the Prefrontal Cortex 
Exploring glutamate dynamics in the prefrontal cortex (PFC) is crucial to 
fully understanding the etiology of ADHD (Arnsten and Li 2005, Arnsten 2009), 
specifically with regards to using the SHR as a model of ADHD (Sagvolden, 
Johansen et al. 2005, Johansen, Killeen et al. 2009). First, tonic glutamate levels 
were examined between the SHR, a model of ADHD (n=8), and its progenitor 
strain, the WKY control (n=8). Multiple regions of the PFC, including the cingulate, 
prelimbic and infralimbic cortices, were sampled. No significant differences in tonic 
glutamate in any of these regions were observed between strains (average tonic 
glutamate – SHR: cingulate 3.7 ± 1.4 µM, prelimbic 3.2 ± 1.2 µM, infralimbic 3.1 ± 
1.2 µM; WKY: cingulate 1.8 ± 0.24 µM, prelimbic 1.6 ± 0.36 µM, infralimbic 2.0 ± 
0.53 µM) – Figure 3.2a. 
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Next, local applications of KCl were used to evoke glutamate release in 
order to examine the release properties of glutamatergic neurons terminating in 
the different PFC sub-regions. Using a two-way repeated measures ANOVA, a 
significant interaction between strain and depth was found (F(2,30)=3.94, p=0.03). 
Bonferroni post-hoc comparisons revealed that the differences between the SHR 
(n=8) and WKY (n=9) existed in both the cingulate and infralimbic cortices, where 
the SHR strain had significantly increased glutamate release in response to the 
KCl than the WKY control (Figure 3.2b). Average evoked glutamate – SHR: 
cingulate 22.5 ± 5.31 µM, prelimbic 18.0 ± 4.04 µM, infralimbic 17.1 ± 3.95 µM; 
WKY: cingulate 8.17 ± 2.24 µM, prelimbic 12.3 ± 2.86 µM, infralimbic 3.50 ± 1.55 
µM. Also discovered were a significant effect of depth (F(2,30)=3.82, p=0.03) and 
strain (F(1,15)=5.99, p=0.02) – see Figure 3.2c. Figure 3.2d represents an average 
KCl-evoked glutamate release event in each of the three separate PFC sub-
regions (only the background subtracted traces are shown). 
 
Tonic and KCl-Evoked Glutamate Release in the Striatum and NA Core 
Tonic levels of glutamate were obtained to evaluate the basal dynamics of 
the glutamatergic system in both the SHR (n=8) and WKY (n=9) strains within the 
striatum. Using a two-way repeated measures ANOVA, no significant interaction 
between strain and depth of the electrode in the Str was found, nor were there any 
differences in the effect of strain nor the effect of depth (average tonic glutamate 
– SHR: dorsal 3.4 ± 1.2 µM, intermediate 4.9 ± 2.1 µM, ventral 4.3 ± 1.7 µM, NA 
core 4.0 ± 1.3 µM; WKY: dorsal 1.9 ± 0.64 µM, intermediate 1.7 ± 0.49 µM, ventral 
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1.7 ± 0.45 µM, NA core 1.5 ± 0.40 µM). See Figure 3.3a. 
Using KCl to evoke glutamate release in the SHR (n=8) and WKY (n=9) 
enabled the examination of the vesicular storage and release capabilities of 
glutamatergic neurons. No significant interaction between strain and depth was 
found (F(3,45)=1.56, p=0.21). A significant effect of strain was discovered in the Str 
(F(1,15)=9.21, p=0.008), revealing that the SHR strain had significantly higher KCl-
evoked glutamate in this region as a whole compared to the control WKY. See 
Figures 3.3b and 3.3c (average evoked glutamate – SHR: dorsal 10.5 ± 1.95 µM, 
intermediate 13.5 ± 2.42 µM, ventral 18.8 ± 4.89 µM, NA core 13.5 ± 2.51 µM; 
WKY: dorsal 5.61 ± 0.764 µM, intermediate 6.20 ± 0.921 µM, ventral 6.75 ± 0.927 
µM, NA core 8.91 ± 1.75 µM). Figure 3.3d represents the three local applications 
of KCl which resulted in reproducible glutamate release events in the Str (only the 
background subtracted traces are shown). No significant effect was seen with 
respect to depth (F(3,45)=2.18, p=0.10). 
 
Glutamate Uptake  
Local applications of exogenous glutamate were used to examine 
differences in the uptake kinetics of the glutamate system in the different sub-
regions of the PFC and striatum within the SHR (n=6) and WKY (n=6). There were 
no differences found in the amplitude of the glutamate signal achieved following 
these local applications in the PFC (F(2,20)=0.90, p=0.42) nor the striatum 
(F(3,33)=0.38, p=0.76). A significant effect of strain was found in both the PFC 
(F(1,10)=5.37, p=0.04) and striatum (F(1,11)=5.43, p=0.03) when examining the 
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volume of exogenous glutamate applied to attain similar amplitudes in these 
regions, though no significant interaction between strain and depth was found in 
either of these brain areas – see Table 3.2. In the PFC, it was discovered that a 
significant effect of strain existed in the amplitude per volume glutamate applied 
(Figure 3.4a, F(1,10)=5.88, p=0.03), illustrating that the SHR strain had a 
significantly smaller amplitude/volume ratio in the PFC as a whole region; however, 
no differences were discovered in the amplitude per volume glutamate applied in 
the striatum (Figure 3.4b). 
 
Discussion 
Using microelectrode array (MEA) technology, aberrant glutamate signaling 
was discovered in the spontaneously hypertensive rat (SHR) model of ADHD-C 
compared to its progenitor strain, the Wistar Kyoto (WKY). Glutamate, an 
excitatory neurotransmitter that functions on a sub-second timescale, must be 
tightly regulated for proper neuronal control (Danbolt 2001). Rapid temporal 
resolution cannot be achieved using microdialysis, which yields results only as 
quickly as every few minutes, missing much of the dynamic changes. Direct 
glutamate measures using MEAs allow for the spatial and temporal resolution 
necessary to examine this system in a quasi-physiologically relevant state, 
enabling the discovery of quickly changing glutamate dynamics in anesthetized 
rodents. Thus, direct glutamate signaling was able to be fully investigated in the 
eight week old SHR. This age was used because it has previously been found that 
the age of eight weeks in rodents is analogous to late adolescence and/or young 
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adulthood in humans (Andreollo, Santos et al. 2012). The Multimodal Treatment 
Study of Children with ADHD (MTA) followed children with ADHD for 14 months 
during treatment (behavior therapy alone, medication alone, or both) and roughly 
8 years after its completion, when the participants were reaching late adolescence 
and young adulthood, it was discovered that more than 60% of children treated 
with medication during the initial 14 month long MTA study had stopped taking any 
medication for their ADHD symptoms (Molina, Hinshaw et al. 2009) and there was 
no long term benefit found in the medication group. For that reason, investigations 
into the neurobiological basis of ADHD in the adolescent population would greatly 
benefit these individuals if it were possible to better target their ADHD symptoms 
using novel pharmacotherapies. 
Previous investigations into the neurochemistry of the SHR, which has been 
discovered to exhibit hyperactive/impulsive and inattentive behaviors (Russell 
2011), have revealed that the SHR has a hypodopaminergic state in the PFC and 
ventral striatum (Miller, Pomerleau et al. 2012, Miller, Thomas et al. 2013). To our 
knowledge, there are currently no studies reporting on direct glutamate 
neurotransmission in these strains, although multiple studies have implicated 
altered glutamate dynamics in the SHR. Activation of NMDA receptors in the SHR 
resulted in less calcium uptake into PFC slices compared to the WKY (Lehohla, 
Kellaway et al. 2004) and glutamate in PFC slices was found to enhance 
norepinephrine release by activation of AMPA receptors and this enhancement 
was augmented in the SHR (Russell 2001). Also found was increased glutamate-
stimulated release of dopamine in the substantia nigra of the SHR compared to 
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the WKY, suggesting altered glutamate regulation of dopaminergic neurons in the 
SHR (Warton, Howells et al. 2009). However, in order to better understand the 
pathophysiology of ADHD and lead us to new categories of medications for the 
treatment of ADHD, direct glutamate signaling must be investigated. 
The PFC is involved in a number of executive functions in both humans and 
rodents, including reward processing and attention (Perry, Joseph et al. 2011), as 
well as learning and memory (Kahn, Ward et al. 2012) and a possible dysfunctional 
role of the PFC in ADHD has been implicated in recent studies (Arnsten 2009). In 
this study, the SHR was found to have higher potassium-evoked glutamate release 
in the cingulate and infralimbic cortices, but not the prelimbic cortex, compared to 
the WKY control. The glutamate release differences in these brain regions furthers 
the theory that the PFC is heavily involved in ADHD, as the cingulate cortex plays 
a vital role in emotional regulation in humans (Granziera, Hadjikhani et al. 2011) 
and is thought to link behavioral outcomes to motivation (Adey 1951, Adey and 
Meyer 1952), while the infralimbic cortex is involved with attention to stimulus 
features, task contingencies, and attentional set-shifting (Dalley, Cardinal et al. 
2004) – all behaviors known to be affected in individuals with ADHD (Krusch, 
Klorman et al. 1996, Mehta, Goodyer et al. 2004, Klimkeit, Mattingley et al. 2005). 
The increase in potassium-evoked glutamate is likely due to increased stores of 
vesicular glutamate or increased levels of docked and primed vesicles. Although 
there was observed a difference in glutamate release between strains, no 
differences in tonic glutamate were found. While applications of potassium evoked 
distinct differences in glutamate release between the SHR and WKY, the evoked 
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increase in glutamate was transient and the tonic levels of glutamate were quickly 
restored. As our lab has shown previously (Hascup, Hascup et al. 2010), only 
about 50% of tonic glutamate is neuronal in origin and thus may not be reflected 
in the levels measured here. Furthermore, tonic glutamate has been shown to be 
negatively affected by the anesthetics used, specifically by urethane (Rutherford, 
Pomerleau et al. 2007). Future studies are needed in awake animals (to evaluate 
differences in tonic glutamate between these strains without the use of anesthesia 
during the neurochemical measurements, though all of the animals in this study 
were anesthetized to the same degree with urethane and can be considered 
comparable to each other. Moreover, the results from this anesthetized study were 
needed to help locate the best brain region to place the MEA for un-anesthetized 
studies moving forward. Because we didn’t see any differences in glutamate 
uptake kinetics in this region, it’s unlikely that the similarities in tonic glutamate 
between strains are due to faster glutamate uptake in the SHR, but instead are 
caused by a similar resting state of the glutamate systems in these strains. For this 
reason, the observed differences in vesicular storage capabilities of the neurons 
terminating in the PFC likely contribute to the increased release of glutamate in the 
PFC during potassium stimulation in the SHR.  
Interestingly, we discovered differences in the volume of glutamate solution 
needed to achieve similar amplitudes following local applications with exogenous 
glutamate in the PFC of the SHR compared to the WKY control, suggesting that 
the uptake mechanisms in the PFC of the SHR are more active. Another important 
finding discovered while examining glutamate uptake in the PFC was the 
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difference in the amplitude per volume of solution applied in this brain area, a 
parameter that was unchanged in the striatum. Previous work from our lab has 
shown that the relationship between amplitude and amount of locally applied 
dopamine solution has a positive linear correlation (Cass and Gerhardt 1995, 
Hebert, Larson et al. 1999), indicative of normal dopamine transporter function, 
and reflects an in vivo Bmax, which allows for the examination of unoccupied 
transporter sites (Cass, Zahniser et al. 1993, Cass and Gerhardt 1995, Hoffman 
and Gerhardt 1998). Assuming that the glutamate transporters obey similar 
principles as the dopamine transporter, the amplitude of glutamate per volume 
applied is a useful tool to investigate glutamate uptake dynamics. In that regard, 
the SHR had a lower amplitude/volume ratio compared to the WKY control, 
indicative of increased glutamate uptake activity. Additionally, the time to clear 
80% of the exogenous glutamate was shorter in the PFC of the SHR, though no 
differences in distinct sub-regions within the PFC were observed. These findings 
could be due to feedback from the increased activity of the NMDA and AMPA 
receptors in the PFC of the SHR (Russell 2001, Lehohla, Kellaway et al. 2004) and 
it’s possible that this feedback occurred prior to our uptake recordings to 
compensate for the increased sensitivity to glutamate. Furthermore, future 
experiments should explore the role of glial uptake in the PFC of these strains, 
perhaps by using the GLT-1 activator ceftriaxone. Finally, both the excitatory and 
inhibitory sub-populations of the metabotropic glutamate receptors (mGluRs) may 
be dysfunctional due to the increased vesicular glutamate storage and the potential 
for release, though the role of these receptors have yet to be investigated in these 
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strains. The results from the PFC in this study reveal that it is imperative to study 
the neurochemical link to ADHD-like behaviors in the SHR. Specifically, the 
glutamate-selective microelectrode array should likely be placed in the PFC region, 
though within which subregion is still open to interpretation. When the animal has 
recovered from the implantation, it should be required to perform some PFC-
dependent cognitive task, such as sustained attention and attentional set shifting 
(Berridge, Shumsky et al. 2012), while glutamate measurements are taken.  
In addition to the PFC, the striatum was included because of its involvement 
with movement processing (dorsal) and the reward circuitry (ventral), both features 
disrupted in ADHD (Balleine, Delgado et al. 2007, Dunnett and Lelos 2010, 
Salamone and Correa 2012). This study discovered that the SHR displayed 
increased evoked glutamate release compared to the WKY control in the striatum 
as a whole; however, no differences in tonic glutamate in any of the striatal sub-
regions were found. The increase in glutamate release, much like in the PFC, is 
likely due to increased intracellular stores of vesicular glutamate. This is the first 
study to uncover direct glutamate signaling differences in the striatum between the 
SHR model of ADHD-C. Previously, our lab discovered decreased potassium-
evoked release of dopamine in the dorsal striatum in the SHR compared to the 
WKY model of ADHD inattentive type (Sagvolden, Dasbanerjee et al. 2008), as 
well as faster uptake in the ventral striatum and nucleus accumbens compared to 
the WKY control strain (Miller, Pomerleau et al. 2012). It has been shown that 
increased stimulation of the D4 and D2 receptors resulted in decreased AMPA and 
NMDA receptor signaling, respectively (Kotecha, Oak et al. 2002, Yuen, Zhong et 
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al. 2010). Decreased activation of these receptors is likely causing hyperactivity of 
the AMPA and NMDA receptors, resulting in increased sensitivity to the release of 
glutamate in the striatum of the SHR. Moreover, an increase in the glutamate-
stimulated release of dopamine in the SHR substantia nigra was discovered in vitro 
(Warton, Howells et al. 2009), which would ordinarily project to the more dorsal 
regions of the striatum, though how this translates to in vivo glutamate signaling in 
the striatum is not fully understood. Future research should examine more closely 
the role of the ionotropic receptors (AMPA and NMDA) as well as the mGluRs in 
this rodent model of ADHD. 
 
Conclusions 
 Although current medications for ADHD appear to be largely successful on 
the surface, many problems still exist (Charach, Yeung et al. 2011). Stimulant 
medications, such as methylphenidate and amphetamines, do not successfully 
treat all people with ADHD and occasionally need to be stopped due to negative 
side effects (Cascade, Kalali et al. 2010). Adolescents and adults with ADHD 
notoriously do not like how stimulants make them feel and “change” their 
personality. This same population is also at risk for abusing their medication for a 
high or diverting/selling their medicine to others (Cowles 2009). In addition, the 
Multimodal Treatment Study of Children with ADHD, a 14-month long study 
following children diagnosed with ADHD, found that eight years post-study, when 
the participants with ADHD were reaching late adolescence, over 60% of 
participants had stopped taking any medication for their ADHD symptoms (Molina, 
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Hinshaw et al. 2009). These data suggest that adolescents with ADHD would 
benefit from medications targeting neurotransmitter systems other than 
catecholamines. Understanding the role of glutamate in ADHD and drugs that can 
modulate it properly without direct involvement of the catecholamine pathways 
should open a new mechanism of action for the treatment of ADHD. 
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Chapter Three: Figures 
 
Figure 3.1 Glutamate-Selective Measurements 
a Glutamate oxidase enzyme was mixed into a BSA/gluteraldehyde matrix and 
coated onto the bottom pair of Pt recording sites. When glutamate came into 
contact with the enzyme, it was converted into α-ketoglutarate, which was blocked, 
and the reporter molecule H2O2. An applied potential of +0.7 V was used to oxidize 
the H2O2 into two electrons and measured by the FAST16mkIII recording system. 
The top pair of Pt recording sites only received the BSA/gluteraldehyde matrix, 
which was not selective for glutamate. The pipette was placed in the center of the 
4 Pt sites, allowing for the even diffusion of locally applied solution across all 4 
sites. b An exclusion layer of mPD was electroplated onto all four Pt recording 
sites. This enabled the blockage of large molecule interferents, such as dopamine 
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and ascorbic acid. c Signals were achieved on both the glutamate oxidase coated 
(glutamate selective) Pt recording sites (green) and the matrix-only (background 
selective) Pt recording sites (gray). When the background was subtracted from the 
glutamate signal, tonic levels of glutamate were observed (black). Only the traces 
from 1 glutamate oxidase coated and 1 matrix-only coated Pt sites are shown. d 
MEA placement into the striatum and e PFC. Cell bodies observed via Nissl stain 
(Miller, Pomerleau et al. 2014). 
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Figure 3.2 Glutamate Dynamics in the Prefrontal Cortex 
a No differences in tonic glutamate levels between the SHR (red) and WKY (black) 
strains were observed in the PFC sub-regions. b The SHR strain was found to 
have significantly increased KCl-evoked glutamate release in the cingulate and 
infralimbic cortices of the PFC (*p<0.05), but not the prelimbic region, compared 
to the WKY control strain. c When examining the PFC as a whole, the SHR strain 
exhibited higher evoked glutamate release than the WKY control. d Comparisons 
of the representative KCl-evoked (black arrows) glutamate release events in each 
of the PFC sub-regions between strains. Mean ± SEM (Miller, Pomerleau et al. 
2014). 
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Figure 3.3 Glutamate Dynamics in the Striatum 
a No differences in tonic glutamate levels between the SHR (red) and WKY (black) 
strains were observed in the striatal sub-regions. b No differences in evoked 
glutamate release existed between strains in the striatal sub-regions, c though it 
was discovered that the SHR had increased evoked glutamate release in the 
striatum as a whole compared to the control WKY (**p<0.01). d Representative 
traces from the background subtracted signals showing three reproducible KCl-
evoked (black arrows) glutamate peaks in the Str. Mean ± SEM (Miller, Pomerleau 
et al. 2014). 
 
 
 
 
 
81 
Figure 3.4 Glutamate Uptake 
a An effect of strain in the PFC when the amplitude per nanoliter of exogenous 
glutamate applied was found, revealing the SHR model of ADHD had a smaller 
amplitude/volume. b No differences existed in the size of the glutamate signal per 
volume applied in the striatum. Mean ± SEM (Miller, Pomerleau et al. 2014). 
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Chapter Three: Tables 
Table 3.1 S2 Microelectrode Array Specifications 
 
 
WKY Control SHR Model of ADHD-C 
Slope (nA/µM) 0.0075 ± 0.00098 0.011 ± 0.00012 
Limit of Detection (µM) 0.99 ± 0.23 0.44 ± 0.090 
Selectivity 223 ± 108 373 ± 89 
No significant differences were observed in the performance of the S2 
microelectrode arrays used between strains. Mean ± SEM. 
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Table 3.2 Glutamate Uptake 
 
 
WKY Control SHR Model of ADHD-C 
Striatum PFC Striatum PFC 
Amplitude (µM) 17 ± 7.0 24 ± 11 22.± 8.4 18 ± 7.1 
Volume (nl) 148 ± 60 161 ± 72 269 ± 102 * 315 ± 119 * 
No differences were found in the size of the glutamate signals achieved following 
local application with exogenous glutamate. A significant effect of strain was found 
to exist in both the striatum and PFC when examining the volume required to 
achieve similar sized glutamate peaks, revealing that the SHR strain required 
significantly more glutamate (*p<0.05). 
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Chapter Four: Multi-Site Neurochemical Recordings: The Pathway to 
Understanding Systems Neuroscience in Freely-Moving Animals 
 
Introduction 
The aberrant regulation of neurotransmitters has been implicated in 
numerous disease states including schizophrenia, Parkinson’s disease, 
Alzheimer’s disease, mood disorders, attention-deficit/hyperactivity disorder 
(ADHD), and drug addiction (Brambilla, Perez et al. 2003, Moghaddam and Javitt 
2012, Lesch, Merker et al. 2013, Paula-Lima, Brito-Moreira et al. 2013, Poletti and 
Bonuccelli 2013, Quintero 2013). Investigations into these molecules via neuronal 
signaling allows for the recording of a signal from an individual neuron (unit 
recordings) or the examination of an entire brain network (local field potentials) 
(McCracken and Grace 2013, Younts, Chevaleyre et al. 2013). While each method 
has its own advantages and disadvantages, they each provide a unique pathway 
to understanding neurotransmitter systems. 
Glutamate, the major excitatory neurotransmitter in the CNS, is present 
throughout the brain (Danbolt 2001). One glutamate-rich region is the frontal cortex 
(FC). Deficits in this area have been found to cause poor impulse control, 
distractibility, hyperactivity, forgetfulness and poor organization and planning 
(Stuss and Levine 2002). The FC is organized into different cortical layers, 
including the cingulate cortex, prelimbic cortex, infralimbic cortex, and the dorsal 
peduncle. Each of these sub-regions within the FC has interneurons that can 
communicate with other FC regions, in addition to the afferent and efferent 
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connections to numerous brain structures (Dalley, Cardinal et al. 2004). To 
understand this complex cortical system and how glutamate dysfunction in these 
region facilitates behavior and disease, it is crucial to understand glutamate’s 
modulating system in this region with minimal disruption. The development of 
microelectrode arrays (MEAs) that can record neurotransmitters in multiple sub-
regions along the dorsal-ventral axis simultaneously in discrete brain regions in 
freely-moving animals during an array of behavior tasks allows us the unique 
opportunity to examine neurotransmitter system dysfunction in an intact system.  
Glutamate dysfunction has been implicated in ADHD in numerous studies, 
including recent clinical proton magnetic resonance spectroscopy studies which 
have discovered elevated levels of a marker for glutamate/glutamine in the frontal 
cortex (FC) of ADHD individuals compared to their normal peers (Moore, 
Biederman et al. 2006). The spontaneously hypertensive rat (SHR), a model of 
ADHD, has been discovered to have aberrant glutamate signaling in the FC in an 
anesthetized experimental paradigm (Miller, Pomerleau et al. 2014); however, no 
studies have focused on glutamate signaling in the freely-moving SHR while 
observing the ADHD-like behavior of the SHR. The purpose of this study was to 
use novel linear array, double sided MEA technology, which allows us to measure 
glutamate dynamics simultaneously within the cingulate, prelimbic, infralimbic and 
dorsal peduncle cortices of the FC. To our knowledge, this was the first time that 
glutamate was recorded simultaneously in multiple brain regions in the freely-
moving SHR. 
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Materials and Methods 
Animals 
Male, 7 week old spontaneously hypertensive rats (SHR) were obtained 
from Charles River Laboratories (NCrl, Wilmington, MA). Male, 7 week old Wistar 
Kyoto (WKY) rats were obtained from Harlan Laboratories (NHsd, Indianapolis, 
IN). Animals were given access to food and water ad libitum and housed in a 12 
hour light/dark cycle. All animals remained in a quarantine period for one week 
before experimental procedures to ensure no travel-related stress confounds were 
possible. During this time, each animal was handled daily to eliminate handling 
stress during the experiment. 
 
Electrode Preparation 
Double-sided paired-row 8 (DSPR8) microelectrode arrays (MEAs) were 
used for all described experiments and consisted of 4 Pt sites on the front and 4 
separate Pt sites on the back, each measuring 15 x 333 µm arranged vertically 
(Figure 4.1A). A 100 µm space separated the tip of the MEA from the first Pt sites, 
1 mm separated the 1st and 2nd pairs as well as the 2nd and 3rd pairs. Finally, 2 mm 
separated the 3rd and 4th pairs. This spacing scheme allowed for simultaneous 
electrochemical detection in multiple brain regions along the dorsal-ventral axis. 
To make the DSPR8s sensitive to glutamate, 1% bovine serum albumin (BSA; 
Sigma-Aldrich, St. Louis, MO), 0.125% glutaraldehyde (Glut; Sigma-Aldrich), and 
1% glutamate oxidase (GluOx; US biological, Salem, MA) were prepared and 
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coated onto the front 4 recording sites to allow for the conversion of glutamate to 
α-ketoglutarate and the reporter molecule, H2O2 (Burmeister and Gerhardt 2001). 
The 4 back recording sites, or the sentinel sites, only received a coating of the 
BSA/Glut matrix to allow for background measures and subtraction to obtain a self-
referenced glutamate signal (Burmeister and Gerhardt 2001, Hinzman, Thomas et 
al. 2010).  
After the DSPR8 MEAs were made sensitive for glutamate, they were built 
into an implantable head-cap (Figure 4.1B). Both ends of a piece of 1 inch long 30 
American wire gauge varnished copper wire (Radioshack, Fort Worth, TX) were 
scraped (~0.25 cm) and fluxed (#186 Rosin flux type RMA, Kester). One end of 
the copper wire was soldered using eutectic solder and a low heat soldering iron 
(200°C) to a gold plated-socket (Ginder Scientific, Nepean, ON). The other end of 
the copper wire was soldered to holes within the stubbed paddle portion of the 
DSPR8. The 8 gold pins (one for each Pt recording site) were inserted into a 9 pin 
ABS plug (Ginder Scientific, Nepean, ON) and the copper wires were wrapped 
around the body of the ABS plug. A reference electrode, consisting of a 1 inch 
Teflon-coated silver wire (200 µm bare, 275 µm coated; A-M Systems, Carlsberg, 
WA), was scraped similar to the copper wires and soldered into a gold plated-
socket and then placed into the ABS plug. The entire assembly was then finished 
with a heavy layer of marine-quality epoxy (Loctite Quick Set Epoxy, Home Depot, 
Atlanta, GA) and allowed to cure for at least 24 hours to ensure a water-proof 
product (Rutherford, Pomerleau et al. 2007, Hascup, Hascup et al. 2011). Finally, 
at least 2 days before the MEAs were surgically implanted, 1,3–phenylenediamine 
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(mPD, Acros, Fisher Scientific, Waltham, MA), a molecular size exclusion layer, 
was electroplated onto both the GluOx and sentinel sites to eliminate interferent 
molecules such as ascorbic acid and dopamine from reaching the Pt sites 
(Hinzman, Thomas et al. 2010).  
 
In Vitro Calibration  
High-speed amperometric recordings, displayed at a frequency of 40 Hz, 
were performed using the FAST16mkIII electrochemical recording system (Fast 
Analytical Sensing Technology, Quanteon, LLC, Nicholasville, KY). Immediately 
before in vivo implantation, an in vitro calibration, as described previously 
(Hinzman, Thomas et al. 2010), was used to determine selectivity (glutamate vs. 
ascorbic acid), limit of detection (in µM, S/N=3), and sensitivity (slope, pA/µM). The 
mean slope, limit of detection and selectivity for electrodes used are presented in 
Tables 4.1 and 4.2 for experiments 1 and 2, respectively. No significant differences 
in the performance of the MEAs used between strains were observed. An example 
in vitro calibration is represented in Figure 4.2. The 4 front recording sites, which 
are glutamate-sensitive, responded only to glutamate and the reporter molecule 
H2O2, whereas the 4 back sentinel recording sites only responded to the reporter 
molecule H2O2. 
 
Implantation Surgery  
After calibration and selection of MEAs, animals were prepared for surgery. 
Immediately before surgery, rats were given injections of carprofen (Rimadyl®, 
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Pfizer, Inc., New York City, NY; 10 mg/kg, s.c.) and 1 ml of 0.9% NaCl (s.c.). 
Isoflurane (Isothesia, Butler Schein, Dublin, OH) was used as the anesthetic for all 
survival surgeries. Initial anesthesia was induced with 4% isoflurane, and once the 
rat was secured in the stereotaxic frame (David Kopf Instruments, Tujunga, 
California), the isoflurane level was reduced to 2.5%, but the levels of isoflurane 
ranged between 3% and 1% during surgery depending on the breathing style of 
each animal. Artificial tears (Rugby Laboratories, Inc., Duluth, GA) were applied to 
the rat’s eyes. The rat’s head was shaved, and 3 applications each of Povidone 
scrub (The Butler Co., Columbus, OH) and ethanol (70%) were used to disinfect 
the surgery site. A craniotomy was performed, and 5 holes were drilled: 1 for the 
MEA, 1 for the reference electrode, and 3 for anchoring skull screws (Amazon, part 
#B00FN0K02). After the skull screws were placed in the skull, dura was reflected 
and the MEA was stereotaxically placed in the FC (from bregma: AP +3.2 mm and 
ML -0.8 mm; from the surface of the brain: DV -5.5 mm) (Paxinos and Watson 
2009). The reference electrode was positioned in its placement hole. Multiple 
applications of dental cement (Ortho Jet Powder and Jet Acrylic Liquid, Lang 
Dental Manufacturing Co., Wheeling, IL) were used to secure the microelectrode 
array assembly to the rat’s skull. The animal was then monitored for the next two 
days and given daily injections of 10 mg/kg carprofen and 1 ml 0.9% NaCl (both 
administered s.c.). On the third day post-surgery, behavior and glutamate 
recordings began. Protocols for animal use were approved by the Institutional 
Animal Care and Use Committee, which is Association for Assessment and 
Accreditation of Laboratory Animal Care International approved. All procedures 
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were carried out in accordance with the National Institutes of Health Guide for Care 
and Use of Laboratory Animals. 
 
Recording Apparatus 
The recording apparatus consisted of a large wooden box with an open-
field activity box (Omnitech Electronics Inc, Columbus, OH) inside and was used 
for all behavior measures. Additionally, a clear insert was used to allow the animals 
to have unrestricted movement. The recording head-stage consisted of a miniature 
connector with 9 connector pins (one connecting each of the 8 channels and one 
connecting the reference electrode). The connector pins lead to a novel grounded 
8-channel low-noise potentiostat to reduce noise (Rat-hat; Quanteon). Connecting 
wires, encompassed by an insulator, lead to the low torque commutator at the top 
of the box. The recording assembly hung from the top center of the box from an 
18 lead commutator (Airflyte, Bayonne, NJ) – see Figures 4.1C and 4.1D. This 
allowed the animal to freely move to all areas of the box (Rutherford, Pomerleau 
et al. 2007). Figure 4.2B represents an in vivo recording performed at 40 Hz. 
 
Methylphenidate Administration 
Methylphenidate (MPH) HCl [threo-methyl-α-phenyl-α-(2-piperidyl)acetate 
hydrochloride; M2892; Sigma-Aldrich, St. Louis, MO] was dissolved in 0.9% saline 
(2 mg/ml solution). Clinically, stimulants are administered orally and exert 
therapeutic actions at low doses that result in peak plasma concentrations within 
the range of 8 to 40 ng/ml (Swanson and Volkow 2002). Although MPH is 
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administered orally for the treatment of ADHD, the majority of studies that have 
examined the behavioral, neurochemical, and electrophysiological actions of 
moderate and high dose stimulants in rodents used intraperitoneal (i.p.) or 
subcutaneous (s.c.) administration (Kuczenski and Segal 2005). Moreover, s.c. 
administration has more rapid pharmacokinetics than oral administration (Wargin, 
Patrick et al. 1983), allowing changes in glutamate to occur while the animal is 
tethered, and is easiest to administer while the animal is tethered and in the open-
field box. 
 
Experiment 1: Daily Behavior and Glutamate Measurements 
Behavior and glutamate recordings began on the third day post-MEA 
implant. Recordings were performed during the animal’s light cycle to reduce any 
effects of foraging (Jensen, Collier et al. 1983). Additionally, the majority of studies 
focused on SHR behavior have been completed during the light cycle (Kuczenski 
and Segal 2001, Mc Fie, Sterley et al. 2012) and studies have shown that MPH 
administration during the dark cycle failed to produce sensitization (Kuczenski and 
Segal 2002). The animal was removed from the home cage, tethered to the 
commutator, and placed into the behavior box. The total distance traveled was 
measured in 5 minute time bins over the course of the session using Oasis 
software. A single injection of MPH (2 mg/kg, s.c.) was administered 3 hours after 
the animal was tethered and a stable baseline was reached. 3 hours following 
MPH, the animal was removed from the recording apparatus and returned to its 
home cage. After each recording session, the recording chamber was cleaned with 
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Roccal disinfectant (Pfizer, Inc., New York City, NY). Additionally, the experimenter 
occasionally entered the room to monitor the animal and check to ensure that the 
tether was not tangled. This procedure was repeated for up to 2 weeks (Table 4.3). 
 
Experiment 2: Alternate Days of Behavior and Glutamate Measurements 
Behavior and glutamate recordings began on the third day post-MEA 
implant. The animal was removed from the home cage, tethered to the 
commutator, and placed into the behavior box. A saline injection (s.c.) was 
administered 1 hour into the start of the experiment, after a stable baseline had 
been achieved. 1 hour later, MPH was given (2 mg/kg, s.c.). Finally, the animal 
was left in the behavior box for another 3 hours for behavior and glutamate 
recording, for a total of 5 recording hours. The animal was then removed from the 
recording apparatus and returned to its home cage. On the second day, the same 
process, minus the tethering to the commutator, was performed. This was to 
reduce the stress on the area around the head-cap and to evaluate the effects of 
the tether on the longevity of the MEA implant as well as the animal’s behavior. 
This procedure was repeated for up to 2 weeks (Table 4.3). 
 
Histology 
Following either the head-cap being dislodged by the animal or completion 
of the 2 week drug administration, the animals were euthanized and brains were 
removed and processed (frozen) for histological evaluation of microelectrode 
recording tracks. No animals were excluded due to an error in electrode placement. 
93 
 
Data Analyses 
Collected glutamate data were analyzed using a custom Matlab®-based 
analysis package. Tonic glutamate and behavior data were averaged to 5 minute 
bins. Behavior data was analyzed within subject using Prism (GraphPad 6.0), with 
significance set to p=0.05. 
 
Results 
Experiment 1: Simultaneous Glutamate Recordings in Multiple Sub-Regions within 
the Frontal Cortex: Daily Recordings 
Figures 4.3 and 4.4 represent each recording region within the FC and the 
average tonic levels over the course of the experiment. Each point is a 5 minute 
tonic average, with the MPH (2 mg/kg) administered half-way through the 
recordings. The SHR has higher tonic glutamate in the cingulate cortex compared 
to the WKY (SHR, 50 µM; WKY, 10 µM), regardless of treatment day (Figures 
4.3A, 4.4A). Tonic levels were similar between the SHR model of ADHD ad the 
WKY control strain in the prelimbic region (SHR, 15 µM; WKY, 15 µM; Figures 
4.3B, 4.4B). The WKY has higher tonic glutamate levels in the infralimbic cortex 
compared to the SHR (SHR, 20 µM; WKY, 50 µM), but treatment with MPH may 
reduce those levels (Figures 4.3C, 4.4C). Finally, there appears to be similar tonic 
dynamics in the dorsal peduncle between strains regardless of MPH treatment 
(SHR, 20 µM; WKY, 20 µM; Figures 4.3D, 4.3D). Animal drop-out became an issue 
as the study progressed, likely due to excessive grooming around the head-cap, 
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weakening the connection to the skull and causing it to fall off. See Table 4.3 for a 
reference to animal drop-out. 
 
Experiment 1: Behavioral Recordings in the Spontaneously Hypertensive Rat 
As expected, chronic methylphenidate (MPH, 2 mg/kg, s.c.) treatment 
increased the total distance travelled in both the SHR (1 hour pre- vs post-MPH, 
t(22)=11.54, p<0.0001) and WKY (1 hour pre- vs post-MPH, t(22)=12.31, p<0.0001, 
Figure 4.5). 
 
Experiment 2: Simultaneous Glutamate Recordings in Multiple Sub-Regions within 
the Frontal Cortex: Alternating Days 
Figure 4.6 represents each recording region of the FC and the average tonic 
levels over the course of the second experiment during baseline and post-saline 
administration, while Figure 4.7 shows post-MPH administration. Figures 4.8 and 
4.9 more accurately represent the acute and chronic effects of treatment on tonic 
glutamate. This study differed from experiment 1 because the animals were 
tethered on alternate days instead of daily. The animals received a saline injection, 
in addition to the MPH, to examine the effects of the injection itself. The SHR was 
found to have higher tonic glutamate in the cingulate cortex (SHR, 50 µM; WKY, 
10 µM; Figures 4.6A, 4.7A, 4.8A, 4.9A) the prelimbic cortex (SHR, 100 µM; WKY, 
50 µM; Figures 4.6B, 4.7B, 4.8B, 4.9B) and the infralimbic cortex (SHR, 50 µM; 
WKY, 25 µM; Figures 4.6C, 4.7C, 4.8C, 4.9C) compared to the WKY control strain 
during baseline, post-saline, and post-MPH, regardless of day. The WKY was 
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observed to have higher tonic glutamate in the dorsal peduncle compared to the 
SHR model of ADHD, regardless of day (SHR, 10 µM; WKY, 40 µM; Figures 4.6D, 
4.7D, 4.8D, 4.9D). Moreover, there was no animal drop-out due to head-cap 
failings – see Table 4.3. Likely, this was because tethering caused stress to the 
vulnerable head-cap area in experiment 1. Excessive grooming to that area 
caused irritation and eventually the demise of the head-cap. By limiting the stress 
to that area, we were able to preserve the head-cap for the entire 2 week study 
during experiment 2. 
 
Experiment 2: Behavioral Recordings in the Spontaneously Hypertensive Rat and 
the Effects of Chronic Methylphenidate Treatment 
Experiment 1 demonstrated that tethering each day was stressful to the 
animal and resulted in loss of head-cap before the experiment was able to be 
completed. For experiment 2, the animals were tethered on alternate days to 
examine tether effects (Figure 4.10). The untethered SHR had significantly more 
activity than the tethered SHR during baseline, and more activity than both of the 
WKY groups (F(3,84)=11.59, p<0.0001); however, all animals had similar baseline 
behavior following 11 days of behavior (F(3,81)=0.718, p=0.54, Figure 4.11). Post-
saline administration (s.c.), the SHR had significantly more activity than the WKY 
strain, regardless of tethering (F(3,89)=9.56, p<0.0001) and all animals had similar 
behavior after the saline injection following 11 days of behavior (F(3,92)=2.49, 
p=0.065, Figure 4.12). Finally, the SHR had significantly more activity than the 
WKY strain, regardless of tethering, after acute MPH (2 mg/kg, s.c.) administration 
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(F(3,292)=57.78, p<0.0001). The untethered SHR had significantly more behavior 
activity than the tethered SHR after chronic MPH, and more activity than both of 
the WKY groups (F(3,292)=24.29, p<0.0001, Figure 4.13). Additionally, the tethered 
SHR displayed more activity than the tethered WKY post-chronic MPH. 
 
Discussion 
Glutamate has been implicated in a number of psychiatric diseases and 
disorders, including attention-deficit/hyperactivity disorder (ADHD). There is 
general agreement that ADHD involves weakened FC function (Arnsten 2009) and 
medications may work to strengthen the function of the FC and its connections to 
other brain regions (Barkley, Grodzinsky et al. 1992, Arnsten and Dudley 2005, 
Arnsten and Li 2005). The role of the rodent medial FC, consisting of the cingulate, 
prelimbic and infralimbic regions in humans, has been linked to behavior and 
attention, inhibiting inappropriate responses, and sustaining attention over long 
delays (Goldman-Rakic 1996, Robbins 1996). Deficits in the FC lead to poor 
impulse control, distractibility, hyperactivity, forgetfulness and poor organization 
and planning (Stuss and Levine 2002). The FC receives modulatory dopaminergic 
projections from the ventral tegmental area in the rodent brain. Additionally, the 
thalamus, amygdala and hippocampus each have glutamate connections to the FC, 
resulting in a region that is heavy with both dopaminergic and glutamatergic 
innervations. By understanding the dysfunction within these systems, it may be 
possible to better treat ADHD by more accurately targeting the specific dysfunction 
occurring.  
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Exploring glutamate dynamics in the FC is crucial to fully understanding the 
etiology of ADHD (Arnsten and Li 2005, Arnsten 2009). It has previously been 
shown in the anesthetized spontaneously hypertensive rat (SHR) model of ADHD 
using a depth profile to characterize each sub-region within the FC that these 
regions are not identical in their tonic measurements (Miller, Pomerleau et al. 
2014) and as previously reported, these sub-regions are different from each other 
using the DSPR8 MEA. Additionally, in line with previous work from our laboratory, 
the levels of glutamate observed were within a range of 5 to 50 µM, suggesting 
that these novel DSPR8 MEAs are measuring levels of glutamate similar to MEAs 
used in the past (Rutherford, Pomerleau et al. 2007). This is the first time that 
glutamate recordings have been completed that allowed for multiple region 
exploration in a freely-moving rodent. 
We observed that the total distance traveled increased in the SHR acutely 
after treatment with a clinically relevant dose of the stimulant methylphenidate 
(MPH) and in both the SHR and WKY control after chronic exposure to MPH. This 
increase in activity is consistent with behavioral sensitization in response to chronic 
MPH treatment (Crawford et al. 1998). The increase in activity assured that the 
dose of MPH was appropriate to cause behavior effects and would likely cause 
neurochemical effects as well. 
Using the novel DSPR8 MEA, we discovered that the SHR model of ADHD 
displayed variable glutamate dynamics within the separate sub-regions compared 
to the WKY control strain. In the cingulate cortex, in both experiments, the SHR had 
increased levels of tonic glutamate regardless of day compared to the WKY control 
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strain. These data are supported by a previous study from our laboratory using 
anesthetized SHR and WKY rodents (Miller, Pomerleau et al. 2014). The SHR has 
been found to self-administer cocaine more readily than the WKY control strain 
following chronic exposure to MPH and it’s likely that the increase in tonic glutamate 
in the cingulate region may potentiate the response for self-administration in the 
SHR (Harvey, Sen et al. 2011). Moreover, the prelimbic, infralimbic and dorsal 
peduncle regions exhibited different results in the two separate experiments, 
though the levels were comparable to each other. The time to reach a stable 
baseline in the DSPR8 MEAs appeared to be similar to other glutamate-selective 
MEAs used in the past, taking roughly 30 minutes to be considered stable. To 
minimize the effects of baseline time on tonic measurements, it’s important to 
maximize the recording period in order to obtain the most accurate measurements 
possible. Recordings over 6 hours in the first experiment and 5 hours in the second 
were sufficient to obtain plenty of data during baseline and following MPH 
administration. 
The initial experimental design was aimed at tonic and phasic glutamate 
recordings in multiple FC sub-regions during two weeks of drug treatment; 
however, this was not possible due to technical issues. The animals, with the 
exception of one control rodent, dislodged their implanted head-caps resulting in 
immediate euthanasia. We theorized that the stress of the tether that allows for the 
glutamate recordings increased grooming to the vulnerable area surrounding the 
head-cap. We then designed experiment 2 to allow for glutamate recordings on 
alternate days. The animals still received behavior recordings every day in the 
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open-field box because research has shown that spatial cues are important when 
administering a stimulant for the development of sensitization (Vezina and Leyton 
2009). Experiment 2 was successful in eliminating animal drop-out, as each animal 
was able to complete 11 days of drug treatment before they were euthanized for 
histology purposes. Additionally, in experiment 2, we discovered differences in the 
behavior of tethered and untethered days during the beginning of the experiment, 
or acute recordings. However, by the time the animals had habituated to the task, 
these differences were no longer evident and the tethering did not significantly 
affect behavior in either strain. As a result of these studies, our laboratory is 
revising the head cap and preamplifier assembly (‘rat-hat’) to have a smaller, more 
robust and tolerable configuration for long-term chronic recordings. 
These experiments sought to characterize glutamate signaling in the freely-
moving SHR model of ADHD compared to the WKY control following exposure to 
a clinically relevant dose of MPH. Furthermore, these studies used a novel double-
sided MEA, the DSPR8, to examine differences in multiple brain regions 
simultaneously. The results from these studies demonstrate that it’s possible to 
record from multiple brain regions simultaneously in freely-moving rodents, though 
more studies need to be completed on characterizing the DSPR8 in vivo. 
 
Conclusions 
These experiments sought to characterize glutamate signaling in the awake 
freely-moving SHR model of ADHD compared to the WKY control following 
exposure to a clinically relevant dose of MPH. Furthermore, these studies used a 
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novel double-sided MEA, the DSPR8, to examine differences in multiple brain 
regions simultaneously. The results from these studies demonstrate that it’s 
possible to record from multiple brain regions in awake, freely-moving rodents, 
though more studies need to be completed on characterizing the DSPR8 to 
attempt to eliminate front/back differences causing negative glutamate levels in 
vivo. Furthermore, the results from these studies demonstrate that acute treatment 
with a low-dose of MPH increases activity in the SHR model of ADHD, in 
accordance with previous studies. As expected, chronic MPH treatment caused 
increased behavior in both the SHR model of ADHD and the WKY control, 
representing behavioral sensitization to the stimulant. Moving forward, two weeks 
of stimulant treatment and glutamate measurements in the hyperactive SHR and 
the normal WKY control are possible with a chronic implant if the animal is tethered 
on alternate days.   
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Chapter Four: Figures 
 
Figure 4.1 DSPR8 Microelectrode Array, Implanted DSPR8, and Behavior Set-Up 
A) A 100 µm space separated the tip of the MEA from the first Pt sites, 1 mm 
separated the 1st and 2nd pairs as well as the 2nd and 3rd pairs. Finally, 2 mm 
separated the 3rd and 4th pairs. B) The entire assembly was finished with a heavy 
layer of marine-quality epoxy to ensure a water-proof product. C) The rodent 
tethered to the commutator inside of the behavior box. Inset: Placement of the 
DSPR8 Pt sites (red) in the rodent frontal cortex. D) The recording apparatus 
consisted of a large wooden box with an open-field activity box inside, as well as 
a clear insert, to allow the animals to have unrestricted movement. 
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Figure 4.2 DSPR8 In Vitro Calibration and In Vivo Trace 
The DSPR8 was allowed to baseline for 20 minutes before an addition of 250 µM 
ascorbic acid (AA) was applied to determine any interfering signal. Next, three 
additions of 20 µM glutamate (Glu) were used to determine the limit of detection 
and slope of the MEA. 2 µM dopamine (DA) was used to evaluate its interferent 
effects. Finally, 8.8 µM of the reporter molecule, H2O2, was applied to ensure all 
sites were working. The front 4 Pt sites (black, red, green, and blue solid lines) all 
responded only to glutamate and H2O2, whereas the back sentinel sites (black, red, 
green, and blue dashed lines) only responded to the reporter molecule H2O2. As 
expected, no site responded to either interferent. B) In vivo, tonic glutamate 
recordings were able to be completed on each background-subtracted trace. 
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Figure 4.3 Daily Tonic Glutamate Levels in the Separate FC Sub-Regions of the 
SHR and WKY: Experiment 1 
Multiple day recordings in the FC over the course of 6 hours, with the MPH (2 
mg/kg) administered half-way (green dashed line). Darker colors, earlier in the 
experiment. Light colors, later in the experiment. Blues, WKY. Reds, SHR. Each 
point is a 5 minute tonic average. A) The SHR appears to have higher tonic 
glutamate in the cingulate cortex compared to the WKY, regardless of treatment 
day. B) Tonic levels appear to be similar in the prelimbic region. C) The WKY 
appears to have higher tonic glutamate levels in the Infralimbic cortex, but 
treatment with MPH may reduce those levels. D) There appears to be similar tonic 
dynamics in the dorsal peduncle between strains regardless of MPH treatment. 
WKY n=3, SHR n=4. Mean represented. 
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Figure 4.4 Acute and Chronic Effects of Methylphenidate on Tonic Glutamate 
Levels Using the DSPR8 MEA in the Separate FC Sub-Regions of the SHR and 
WKY: Experiment 1 
Multiple day recordings in the FC over the course of 6 hours, with the MPH (2 
mg/kg) administered half-way (green dashed line). Blue, WKY. Red, SHR. Each 
point is a 5 minute tonic average. A) The SHR displays increased tonic glutamate 
following chronic MPH but not the WKY in the cingulate. B) MPH appears to 
elevate glutamate chronically in both the SHR and WKY prelimbic cortices. C) The 
WKY appears to have higher tonic glutamate levels in the infralimbic cortex, but 
treatment with MPH may reduce those levels. D) MPH appears to elevate 
glutamate chronically in both the SHR and WKY dorsal peduncle. WKY n=3, SHR 
n=4. Mean represented. 
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Figure 4.5 Chronic Effect of Methylphenidate on Total Distance Travelled between 
the SHR and WKY: Experiment 1 
MPH (2 mg/kg, s.c., blue arrow) was found to increase the total distance traveled 
in both the SHR (red) and WKY (black) strains chronically, but to a much greater 
extent in the SHR. 5 minute average behavior bins. ****p<0.0001. SHR n=4, WKY 
n=3. Mean ± SEM. 
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Figure 4.6 Daily Tonic Glutamate Levels in the Separate FC Sub-Regions of the 
SHR and WKY: Experiment 2 
Baseline and saline (s.c., black dashed line) effects on multiple day recordings in 
the prefrontal cortex. Dark colors, earlier in the experiment. Light colors, later in 
the experiment. Blues, WKY. Reds, SHR. Each point is a 5 minute tonic average. 
A) The SHR appears to have higher tonic glutamate in the cingulate cortex 
compared to the WKY, regardless of MPH treatment day. B) The SHR appears to 
have higher tonic glutamate in the prelimbic cortex compared to the WKY. C) The 
SHR appears to have higher tonic glutamate in the infralimbic cortex compared to 
the WKY after continuous treatment with MPH. D) The WKY appears to have 
higher tonic glutamate in the dorsal peduncle compared to the SHR, regardless of 
day. WKY n=2, SHR n=2. Mean represented. 
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Figure 4.7 Daily Tonic Glutamate Levels Using the DSPR8 MEA Post-
Methylphenidate Administration in the Separate FC Sub-Regions of the SHR and 
WKY: Experiment 2 
Baseline and saline (s.c., black dashed line) effects on multiple day recordings in 
the prefrontal cortex. Dark colors, earlier in the experiment. Light colors, later in 
the experiment. Blues, WKY. Reds, SHR. Each point is a 5 minute tonic average. 
A) The SHR appears to have higher tonic glutamate in the cingulate cortex 
compared to the WKY, regardless of MPH treatment day. B) The SHR appears to 
have higher tonic glutamate in the prelimbic cortex compared to the WKY. C) The 
SHR appears to have higher tonic glutamate in the infralimbic cortex compared to 
the WKY after continuous treatment with MPH. D) The WKY appears to have 
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higher tonic glutamate in the dorsal peduncle compared to the SHR, regardless of 
day. WKY n=2, SHR n=2. Mean represented. 
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Figure 4.8 Acute and Chronic Effects of Methylphenidate on Tonic Glutamate 
Levels Using the DSPR8 MEA in the Separate FC Sub-Regions of the SHR and 
WKY: Experiment 2 
Baseline and saline (s.c., black dashed line) effects on multiple day recordings in 
the FC. Blue, WKY. Red, SHR. Each point is a 5 minute tonic average. A) The 
SHR appears to have higher tonic glutamate in the cingulate cortex compared to 
the WKY, regardless of MPH treatment day. B) The SHR appears to have higher 
tonic glutamate in the prelimbic cortex compared to the WKY. C) The SHR appears 
to have higher tonic glutamate in the infralimbic cortex compared to the WKY after 
chronic treatment with MPH. D) The WKY appears to have higher tonic glutamate 
in the dorsal peduncle compared to the SHR, regardless of day. WKY n=2, SHR 
n=2. Mean represented. 
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Figure 4.9 Acute and Chronic Effects of Methylphenidate on Tonic Glutamate 
Levels Using the DSPR8 MEA Post-Methylphenidate Administration in the 
Separate FC Sub-Regions of the SHR and WKY: Experiment 2 
Baseline and saline (s.c., black dashed line) effects on multiple day recordings in 
the FC. Blue, WKY. Red, SHR. Each point is a 5 minute tonic average. A) The 
SHR appears to have higher tonic glutamate in the cingulate cortex compared to 
the WKY, regardless of MPH treatment day. B) The SHR appears to have higher 
tonic glutamate in the prelimbic cortex compared to the WKY before MPH, which 
reduces these levels. C) The SHR appears to have higher tonic glutamate in the 
infralimbic cortex compared to the WKY after chronic treatment with MPH. D) The 
WKY appears to have higher tonic glutamate in the dorsal peduncle compared to 
the SHR, regardless of day. WKY n=2, SHR n=2. Mean represented. 
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Figure 4.10 Tethering 
A) During tethered days (glutamate and behavioral recordings) in experiment 2, 
the animal was attached to the commutator via a tethered cord that allowed the 
animal to reach all areas of the activity box. B) During untethered days (behavioral 
recording only), the animal was not attached to the tether. 
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Figure 4.11 Effects of Tethering on Baseline Behavior Activity 
A) Baseline behavior activity on the first day of tethering (black, day 1) and 
untethering (color, day 2) in the WKY (green squares) and SHR (red circles). The 
untethered SHR had significantly more activity than the tethered SHR during 
baseline, and more activity than both of the WKY groups acutely. B) Baseline 
behavior during the chronic recordings. All animals had similar baseline behavior 
following 11 days of behavior. WKY n=2, SHR n=2, *p<0.05, ***p<0.001. Mean 
represented on left. Mean ± SEM on right. 
 
 
 
 
 
 
113 
 
Figure 4.12 Effects of Tethering on Post-Saline Behavior Activity 
A) Behavior activity post-saline administration (s.c.) on the first day of tethering 
(black, day 1) and untethering (color, day 2) in the WKY (green squares) and SHR 
(red circles). The SHR had significantly more activity than the WKY strain, 
regardless of tethering. B) Behavior activity post-saline administration during the 
chronic recordings. All animals had similar behavior after the saline injection 
following 11 days of behavior. WKY n=2, SHR n=2, **p<0.01, ***p<0.001. Mean 
represented on left. Mean ± SEM on right. 
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Figure 4.13 Effects of Tethering on Post-Methylphenidate Behavior Activity 
A) Behavior activity post-methylphenidate administration (MPH, 2 mg/kg, s.c.) on 
the first day of tethering (black, day 1) and untethering (color, day 2) in the WKY 
(green squares) and SHR (red circles). The SHR had significantly more activity 
than the WKY strain, regardless of tethering. B) Behavior post-MPH administration 
during the chronic recordings. The untethered SHR had significantly more behavior 
activity than the tethered SHR after chronic MPH, and more activity than both of 
the WKY groups. Additionally, the tethered SHR displayed more activity than the 
tethered WKY post-chronic MPH. WKY n=2, SHR n=2, ***p<0.001. Mean 
represented on left. Mean ± SEM on right. 
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Chapter Four: Tables 
Table 4.1 DSPR8 Performance in the WKY and SHR: Experiment 1 
WKY Dorsal Peduncle Infralimbic Prelimbic Cingulate 
Site 1 5 2 6 3 7 4 8 
Slope (pA/µM) 1.7  5.5  9.1  9.8  
Selectivity 92 5.2 218 5.8 185 20 221 17 
LOD (µM) 13 7.3 0.52 133 0.21 12 0.14 7.2 
         
SHR Dorsal Peduncle Infralimbic Prelimbic Cingulate 
Site 1 5 2 6 3 7 4 8 
Slope (pA/µM) 3.3  4.2  6.9  6.3  
Selectivity 142 0.23 64 2.5 183 31 23 4.9 
LOD (µM) 23 280 7.5 92 0.53 115 0.57 23 
No significant differences were observed in the performance of the DSPR8 MEAs 
used between strains. Sites 1, 2, 3, and 4 were the front, glutamate-selective sites. 
Sites 5, 6, 7 and 8 were the back, background recording sites. 
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Table 4.2 DSPR8 Performance in the WKY and SHR: Experiment 2 
WKY Dorsal Peduncle Infralimbic Prelimbic Cingulate 
Site 1 5 2 6 3 7 4 8 
Slope (pA/µM) 3.7  4.1  3.3  4.1  
Selectivity 68 0.71 99 3.7 99 2.5 95 0.29 
LOD (µM) 1.9 423 0.32 17 0.76 25 0.87 270 
         
SHR Dorsal Peduncle Infralimbic Prelimbic Cingulate 
Site 1 5 2 6 3 7 4 8 
Slope (pA/µM) 7.9  2.3  6.8  7.2  
Selectivity 209 5.2 22 5.3 154 8.1 514 21 
LOD (µM) 1.3 99 3.3 145 1.9 131 1.6 137 
No significant differences were observed in the performance of the DSPR8 MEAs 
used between strains. Sites 1, 2, 3, and 4 were the front, glutamate-selective sites. 
Sites 5, 6, 7 and 8 were the back, background recording sites. 
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Table 4.3 Animal Drop-Out 
Experiment 1: Tethered Daily 
Animal # Dislodged Head-Cap & Euthanized 
WKY 1 11 days post-implant 
WKY 2 did not knock off head-cap 
WKY 3 14 days post-implant 
SHR 1 8 days post-implant 
SHR 2 11 days post-implant 
SHR 3 10 days post-implant 
SHR 4 10 days post-implant 
Experiment 2: Tethered on Alternate Days 
Animal # Dislodged Head-Cap & Euthanized 
WKY A Lasted full 2 weeks 
WKY B Lasted full 2 weeks 
SHR A Lasted full 2 weeks 
SHR B Lasted full 2 weeks 
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Chapter Five: Chronic Methylphenidate Treatment Increases Tonic and 
Reduces Phasic Glutamate in the Frontal Cortex of a Freely-Moving Rodent 
Model of ADHD 
 
Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is estimated to affect 6% of 
children worldwide and 50% of those diagnosed will continue to suffer into 
adulthood (Kessler, Adler et al. 2006, Polanczyk, de Lima et al. 2007, Biederman, 
Petty et al. 2011). Adolescents and adults diagnosed with ADHD are more likely 
to suffer from mood and anxiety disorders and to develop drug addiction 
(Biederman, Petty et al. 2010). Methylphenidate (MPH), a dopamine reuptake 
inhibitor, is one of the most commonly prescribed treatments for ADHD (De Sousa 
and Kalra 2012). Animal studies have established the reinforcing effects of MPH 
(Collins, Weeks et al. 1984) and MPH has also been found to serve as a reinforcer 
for children diagnosed with ADHD (Fredericks and Kollins 2004). Debate has been 
ongoing whether stimulant treatment for ADHD makes one more susceptible to 
drug abuse later in life. A meta-analysis of the literature concluded that when 
stimulant treatment for ADHD is initiated during childhood, there is a decreased 
risk for developing a substance use disorder during adulthood (Wilens, Faraone et 
al. 2003). Conversely, when the initiation of stimulant treatment for ADHD occurs 
during adolescence, there is an increased risk of developing a substance use 
disorder (Kollins, MacDonald et al. 2001, Kollins 2008). In rodents, exposure to 
chronic administration of a clinically relevant dose of MPH during adolescence 
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caused the animals to self-administer cocaine more quickly as adults (Harvey, Sen 
et al. 2011). Furthermore, MPH is not always successful and occasionally needs 
to be stopped due to negative side effects (Cascade, Kalali et al. 2010). Together, 
these results suggest that adolescents and adults with ADHD would benefit from 
novel medications for the treatment of ADHD, likely drugs that don’t specifically 
target the catecholaminergic systems. 
Glutamate dysfunction has been implicated in ADHD in an array of studies, 
including both preclinical and clinical studies. Our laboratory has previously shown 
that the spontaneously hypertensive rat (SHR), a rodent model of ADHD, has been 
discovered to have aberrant glutamate signaling (Russell 2001, Lehohla, Kellaway 
et al. 2004, Warton, Howells et al. 2009) in the frontal cortex compared to its 
progenitor strain, the Wistar Kyoto (WKY) (Miller, Pomerleau et al. 2014). Better 
understanding the role of glutamate in ADHD and discovering drugs that can 
modulate it properly without direct involvement of the catecholamine pathways 
should reveal novel treatment options for ADHD. The purpose of this study was to 
examine the role of tonic and phasic glutamate signaling in the prelimbic cortex of 
the freely-moving SHR during an open-field behavior task to measure 
hyperactivity, a key symptom of ADHD. Additionally, the effects of MPH versus 
saline were examined in an effort to discover any exertion of the dopaminergic-
altering stimulant over the glutamatergic system in order to better characterize 
novel pharmacotherapies for the treatment of ADHD. 
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Materials and Methods 
Animals 
Male, 7 week old spontaneously hypertensive rats (SHR) were obtained 
from Charles River Laboratories (NCrl, Wilmington, MA). Male, 7 week old Wistar 
Kyoto (WKY) rats were obtained from Harlan Laboratories (NHsd, Indianapolis, 
IN). Animals were given access to food and water ad libitum and housed in a 12 
hour light/dark cycle. All animals remained in a quarantine period for 1 week before 
experimental procedures to ensure no travel-related stress confounds were 
possible. During this time, each animal was handled daily to eliminate handling 
stress during the experiment. 
 
Electrode Preparation 
Glutamate-oxidase (GluOx) coated microelectrode arrays (MEAs) consisting 
of 4 Pt sites measuring 15 x 333 µm arranged vertically in dual pairs (S2 
conformation) were used as previously described (Burmeister, Davis et al. 2013, 
Miller, Pomerleau et al. 2014). After the S2 MEAs were made sensitive for 
glutamate using 1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), 
0.125% glutaraldehyde (Glut; Sigma-Aldrich), and 1% GluOx (US biological, 
Salem, MA), they were built into an implantable head-cap. Both ends of a piece of 
1 inch long 30 American wire gauge varnished copper wire (Radioshack, Fort 
Worth, TX) were scraped (~0.25 cm) and fluxed (#186 Rosin flux type RMA, 
Kester). One end of the copper wire was soldered using eutectic solder and a low 
heat soldering iron (200°C) to a gold plated-socket (Ginder Scientific, Nepean, 
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ON). The other end of the copper wire was soldered to holes within the stubbed 
paddle portion of the MEA. The 4 gold pins (one for each Pt recording site) were 
inserted into a 9 pin ABS plug (Ginder Scientific, Nepean, ON) and the copper 
wires were wrapped around the body of the ABS plug. A reference electrode, 
consisting of a 1 inch Teflon-coated silver wire (200 µm bare, 275 µm coated; A-
M Systems, Carlsberg, WA), was scraped similar to the copper wires and soldered 
into a gold plated-socket and then placed into the ABS plug. The entire assembly 
was then finished with a heavy layer of marine-quality epoxy (Loctite Quick Set 
Epoxy, Home Depot, Atlanta, GA) and allowed to cure for at least 24 hours to 
ensure a water-proof product (Rutherford, Pomerleau et al. 2007, Hascup, Hascup 
et al. 2011). Finally, at least 2 days before the MEAs were surgically implanted, 
1,3–phenylenediamine (mPD, Acros, Fisher Scientific, Waltham, MA), a molecular 
size exclusion layer, was electroplated onto both the GluOx and sentinel sites to 
eliminate interferent molecules such as ascorbic acid and dopamine from reaching 
the Pt sites (Hinzman, Thomas et al. 2010).  
 
In Vitro Calibration  
High-speed amperometric recordings, displayed at a frequency of 10 Hz, 
were performed using the FAST16mkIII electrochemical recording system (Fast 
Analytical Sensing Technology, Quanteon, LLC, Nicholasville, KY). Immediately 
before in vivo implantation, an in vitro calibration, as described previously 
(Hinzman, Thomas et al. 2010), was used to determine selectivity (glutamate vs. 
ascorbic acid), limit of detection (in µM, S/N=3), and sensitivity (slope, pA/µM). The 
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mean slope, limit of detection and selectivity for electrodes used are presented in 
Tables 5.1. No significant differences in the performance of the MEAs used 
between strains were observed 
 
Implantation Surgery  
After calibration and selection of MEAs, animals were prepared for surgery. 
Immediately before surgery, rats were given injections of carprofen (Rimadyl®, 
Pfizer, Inc., New York City, NY; 10 mg/kg, s.c.) and 1 ml of 0.9% NaCl (s.c.). 
Isoflurane (Isothesia, Butler Schein, Dublin, OH) was used as the anesthetic for all 
survival surgeries. Initial anesthesia was induced with 4% isoflurane, and once the 
rat was secured in the stereotaxic frame (David Kopf Instruments, Tujunga, 
California), the isoflurane level was reduced to 2.5%, but the levels of isoflurane 
ranged between 3% and 1% during surgery dependent upon the breathing style of 
each animal. Artificial tears (Rugby Laboratories, Inc., Duluth, GA) were applied to 
the rat’s eyes. The rat’s head was shaved, and three applications each of Povidone 
scrub (The Butler Co., Columbus, OH) and ethanol (70%) were used to disinfect 
the surgery site. A craniotomy was performed, and 5 holes were drilled: 1 for the 
MEA, 1 for the reference electrode, and 3 for anchoring skull screws (Amazon, part 
#B00FN0K02). After the skull screws were placed in the skull, dura was reflected 
and the MEA was stereotaxically placed in the prelimbic PFC (from bregma: AP 
+3.2 mm and ML -0.8 mm; from the surface of the brain: DV -3.5 mm) (Paxinos and 
Watson 2009). The reference electrode was then positioned into its placement 
hole, sliding along the underside of the skull. Multiple applications of dental cement 
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(Ortho Jet Powder and Jet Acrylic Liquid, Lang Dental Manufacturing Co., 
Wheeling, IL) were used to secure the MEA assembly to the rat’s skull. The animal 
was then monitored for the next 2 days and given daily injections of 10 mg/kg 
carprofen and 1 ml 0.9% NaCl (both administered s.c.). On the third day post-
surgery, behavior and glutamate recordings began. Protocols for animal use were 
approved by the Institutional Animal Care and Use Committee, which is Association 
for Assessment and Accreditation of Laboratory Animal Care International 
approved. All procedures were carried out in accordance with the National Institutes 
of Health Guide for Care and Use of Laboratory Animals. 
 
Recording Apparatus 
The recording apparatus consisted of a large wooden box with an open-
field activity box (Omnitech Electronics Inc., Columbus, OH) inside and was used 
for all behavioral measures. Additionally, a clear insert was used to allow the 
animals to have unrestricted movement. The recording head-stage consisted of a 
miniature connector with 5 connector pins (one connecting each of the 4 channels 
and 1 connecting the reference electrode). The recording assembly hung from the 
top center of the box from an 18 lead commutator (Plastics1, Roanoke, VA). This 
allowed the animal to freely move to all areas of the box (Rutherford, Pomerleau 
et al. 2007). 
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Methylphenidate Administration 
Methylphenidate (MPH) HCl [threo-methyl-α-phenyl-α-(2-piperidyl)acetate 
hydrochloride; M2892; Sigma-Aldrich, St. Louis, MO] was dissolved in 0.9% saline 
(2 mg/ml solution). Clinically, stimulants are administered orally and exert 
therapeutic actions at low doses that result in peak plasma concentrations within 
the range of 8 to 40 ng/ml (Swanson and Volkow 2002). Although MPH is 
administered orally for the treatment of ADHD, the majority of studies that have 
examined the behavioral, neurochemical, and electrophysiological actions of 
moderate and high dose stimulants in rodents used intraperitoneal (i.p.) or 
subcutaneous (s.c.) administration (Kuczenski and Segal 2005). Moreover, s.c. 
administration has more rapid pharmacokinetics compared to oral administration 
(Wargin, Patrick et al. 1983). This method of administration was easiest to 
administer while the animal was tethered and in the open-field box. 
 
Behavior and Amperometry 
Behavior and glutamate recordings began on the third day post-MEA 
implant. Recordings occurred during the animal’s light cycle to reduce any effects 
of foraging (Jensen, Collier et al. 1983). The majority of studies focused on SHR 
behavior have been completed during the light cycle (Kuczenski and Segal 2001, 
Mc Fie, Sterley et al. 2012) and studies have shown that MPH administration 
during the dark cycle failed to produce sensitization (Kuczenski and Segal 2002). 
The animal was removed from the home cage, tethered to the commutator, and 
placed into the behavior box. The total distance traveled was measured in 1 minute 
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time bins over the course of the session using Oasis software. A saline injection 
(s.c.) was administered at an hour after the start of the experiment. MPH was given 
(2 mg/kg, s.c.) 1 hour later. The animal was then left in the behavior box for another 
3 hours for behavior and glutamate recording (Figure 5.1A). During the final 10 
minutes, the voltage applied was changed to +0.2 V vs. the Ag/AgCl reference 
electrode, which removed the oxidation of H2O2 on the MEA Pt recording sites and 
thereby further confirming peroxide-mediated measurements. The animal was 
then removed from the recording apparatus and returned to the home cage. On 
the second day, the same process, minus tethering to the commutator, was 
performed. Previous experiments from our laboratory have shown that this process 
reduces the stress on the area around the head-cap and ensures 2 weeks of drug 
treatment was possible. Alternate days of tethering then continued for a total of 11 
days (Figure 5.1B). After each recording session, the recording chamber was 
cleaned with Roccal disinfectant (Pfizer, Inc., New York City, NY). Additionally, the 
experimenter occasionally entered the room to monitor the animal and check to 
ensure that the tether was not tangled.  
 
Histology 
Following completion of the 2 week drug administration, the animals were 
euthanized and brains were removed and processed (frozen) for histological 
evaluation of microelectrode recording tracks. 2 animals knocked-off their head-
caps on the last day of recordings and the histology was inconclusive. 
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Data Analyses 
Collected glutamate data were analyzed using a custom Matlab®-based 
analysis package. Figure 5.1 explains the experiment timeline and how data was 
picked for analyses. Data for each animal was organized into 3 blocks to examine 
drug effects: 1) acute, day 1 or day 3; 2) intermediate, day 5 or day 7; and 3) 
chronic, day 9 or day 11. Next, the chosen full glutamate data file had a boxcar 
filter, or moving average, of 20 points applied before being separated into 4 
separate 10 minute files per animal per block: 1) saline (90 minutes after the start 
of experiment), 2) treatment 1 (30 minutes post-treatment or 150 minutes after the 
start of experiment), 3) treatment 2 (80 minutes post-treatment or 200 minutes after 
the start of experiment), and 4) treatment 3 (130 minutes post-treatment or 250 
minutes after start of experiment). This created 12 separate data files for each 
animal. Each file was analyzed for the following: 
• Phasic peak criteria (for the subtracted signal): event offset: -2; threshold 
points: 5; peak S/N threshold: 1.5; minimum event spacing: 10; Trise min: 0.25 
• Phasic peak exclusion criteria (for the subtracted signal): control R2: >0.80; 
Trise: <0.25; peak S/N: <2.0; peak area: negative; peak amplitude: negative or 
>5.0 
• Tonic glutamate criterion (for the subtracted signal): first positive phasic peak 
baseline was used as tonic glutamate 
• Tonic glutamate exclusion criteria (for the subtracted signal): negative or below 
the in vitro calibrated LOD 
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Using the above criteria, 8 out of 30 total animals were excluded from intermediate 
treatment tonic glutamate levels. 10 out of 30 animals were excluded from chronic 
treatment tonic glutamate levels. The primary reason for exclusion of these 
animals was because of negative tonic levels, which occurred when the sentinel 
recording sites were measuring a higher current than the glutamate-selective 
recording sites, though phasic signaling was still observed. All data were analyzed 
using two-way repeated measures ANOVAs followed by Bonferroni corrections for 
multiple comparisons (GraphPad Prism 6.0). For all data, significance was set to 
p=0.05. 
 
Results 
Weight Change Post-Implant 
 A significant interaction between treatment (saline or MPH) and day (days 
1-13) (F13,91=3.254, p=0.005), a significant effect of treatment (F1,7=7.169, p=0.03), 
and a significant effect of day (F13,91=37.60, p<0.0001) existed in the WKY control 
group on the amount of weight gained following MEA implantation. The WKY strain 
treated with MPH was found to weigh significantly more than the WKY group 
treated with saline alone during the last four days of the experiment (Figure 5.2A). 
When examining the weights of the SHR group, no interaction was found between 
treatment (saline or MPH) and day (days 1-13), which is consistent with clinical 
data (Vincent, Varley et al. 1990). A two-way repeated measures ANOVA found a 
significant effect of day (F13,78=28.91, p<0.0001), which was expected as the 
rodents were gaining weight as they were reaching young adulthood (Figure 5.2B). 
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Acute, Intermediate, and Chronic Effects of a Clinically Relevant Dose of 
Methylphenidate on Total Distance Traveled in the Open-Field Behavior Task 
For acute behavioral measurements, a significant interaction between 
strain/treatment (WKY saline, WKY MPH, SHR saline, SHR MPH) and time (300 
1 minute bins) (F897,5083=1.717, p<0.0001) as well as significant effects of 
strain/treatment (F3,17=23.57, p<0.0001)  and time (F299,5083=4.471, p<0.0001) 
were found. Baseline activity during the first day of behavioral recordings was 
similar between the SHR and WKY, consistent with previous reports that the 
hyperactive behaviors of the SHR model of ADHD are absent in a novel 
environment (Johansen, Sagvolden et al. 2005, Howells, Bindewald et al. 2009). 
Administration of saline (s.c.) also did not produce any significant differences 
between strains. The difference in activity started 30 minutes following treatment. 
The SHR treated with MPH had significantly higher total distance traveled than the 
SHR treated with saline. Additionally, the SHR MPH group had greater activity than 
the WKY MPH group. These differences lasted for about 90 minutes before the 
groups again displayed similar activity (Figure 5.3). These results are consistent 
with previous studies reporting that a low, clinically relevant dose of MPH 
increased activity in the SHR (Yang, Amini et al. 2003, Amini, Yang et al. 2004). 
For intermediate behavioral measurements, a significant interaction 
between strain/treatment and time (F897,5083=3.110, p<0.0001) as well as 
significant effects of strain/treatment (F3,17=9.153, p=0.0008)  and time 
(F299,5083=4.628, p<0.0001) were found. Baseline activity was found to be similar 
129 
between the SHR and WKY and saline (s.c.) did not produce any significant 
differences between strains. The difference in activity started 30 minutes after 
treatment, similar to the acute recording. The SHR treated with MPH had 
significantly higher total distance traveled than the SHR treated with saline. 
Additionally, the SHR: MPH group displayed increased activity compared to the 
WKY: MPH group (Figure 5.4). These differences lasted longer than they did for 
the acute recordings. It took nearly 120 minutes before the groups again displayed 
similar activity. 
For chronic behavioral measurements, a significant interaction between 
strain/treatment and time (F897,5083=1.805, p<0.0001) as well as significant effects 
of strain/treatment (F3,17=7.293, p=0.003)  and time (F299,5083=3.637, p<0.0001) 
were found. The SHR, regardless of treatment, displayed increased activity during 
the first 5 minutes of the experiment compared to both groups of the WKY, 
consistent with reports that the hyperactive behaviors of the SHR model of ADHD 
become evident after multiple exposures to an environment  
(Knardahl and Sagvolden 1981, Sagvolden, Pettersen et al. 1993, Howells, 
Bindewald et al. 2009). Administration of saline (s.c.) did not produce any 
significant differences between strains. The difference in activity started 30 
minutes after treatment, when the SHR treated with MPH had significantly more 
total distance traveled than the SHR treated with saline (Figure 5.5). These 
differences lasted for 120 minutes before the groups again displayed similar 
activity. The SHR MPH group also had increased activity than the WKY treated with 
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MPH group, beginning 90 minutes post-MPH and this effect only lasted for 
approximately 30 minutes. 
 
Examination of Tonic and Phasic Glutamate Signaling 
Figure 5.6A shows an example of tonic and phasic glutamate signaling over 
the course of the 5 hour experiment in one animal. Three major types of phasic 
signaling are apparent: 1) fast single peaks (5-10 seconds long), 2) fast multi-
peaks (5-10 seconds long), and 3) slower phasic signaling (1-3 minutes long) 
which consisted of many fast multi- and single-peaks (Figure 5.6B). Figure 5.7 
shows the differences in tonic and phasic glutamate between strains and 
treatments. Additionally, Figure 5.7 shows the change in applied potential from 
+0.7 V to +0.2 V vs. Ag/AgCl reference electrode, which is below the H2O2 
oxidation potential.  
 
Intermediate Methylphenidate Treatment Increases Tonic Glutamate Levels in the 
SHR but not the WKY 
A significant effect of time (30 minutes after saline, and 30, 80, and 130 
minutes after treatment) (F3,36=2.866, p<0.05) and an effect of strain/treatment 
(WKY saline, WKY MPH, SHR saline, and SHR MPH) (F3,12=3.710, p<0.05) after 
intermediate treatment with MPH/saline were found, though no interaction 
between the two existed. This data demonstrates that the SHR treated with MPH 
(6.2 ± 1.4 µM) for 1 week has higher tonic levels than the SHR treated with saline 
alone (1.3 ± 1.4 µM). Additionally, the WKY saline group (6.4 ± 1.4 µM) had higher 
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tonic glutamate than the SHR saline group. The WKY MPH group (5.0 ± 1.3 µM) 
was not significantly different than the other groups (Figure 5.8A). 
 
Chronic Methylphenidate Treatment Increases Tonic Glutamate Levels in both the 
SHR and WKY 
Following chronic treatment, a significant interaction between time and 
strain/treatment (F9,39=2.433, p<0.05) and an effect of strain/treatment 
(F3,13=4.009, p<0.05) were found. These data demonstrate that in both the SHR 
model of ADHD and the WKY control, chronic MPH treatment with a clinically 
relevant dose (SHR MPH 9.9 ± 2.1 µM, WKY MPH 10 ± 1.9 µM) increases tonic 
levels of glutamate compared to animals treated with saline alone (SHR saline 3.2 
± 2.1 µM, WKY saline 3.3 ± 2.1 µM) (Figure 5.8B). 
 
Neither Intermediate nor Chronic Methylphenidate Treatment Changes the 
Frequency of Phasic Glutamate Events 
 Figures 5.9A and 5.9B reveal that the number of phasic events per 10 
minute sample did not differ between strain, treatment, nor time. 
 
Chronic, but not Intermediate, Methylphenidate Treatment Reduces Phasic 
Glutamate Signaling in the SHR 
After intermediate drug treatment, no differences in the amplitude of phasic 
glutamate signals were found. Average (± SEM) phasic amplitudes during 
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intermediate treatment were as follows: WKY saline 0.40 ± 0.033 µM, WKY MPH 
0.21 ± 0.018 µM, SHR saline 0.13 ± 0.016 µM, SHR MPH 0.22 ± 0.044 µM. 
Following chronic treatment, a significant effect of strain/treatment (WKY 
saline, WKY MPH, SHR saline, SHR MPH) on phasic glutamate amplitudes 
(F3,22=3.316, p<0.05) was discovered. Also, there was a trend towards an effect of 
time (F3,66=2.413, p=0.07). These data demonstrate that in the SHR, a significant 
difference existed between the MPH (SHR MPH 0.11 ± 0.0056 µM) and saline 
treated animals (SHR saline 0.53 ± 0.0072 µM). No effects of chronic MPH 
treatment on phasic glutamate amplitude were found in the WKY groups (WKY 
saline 0.13 ± 0.011 µM, WKY MPH 0.22 ± 0.011 µM) (Figure 5.10B). 
 
Types of Phasic Signaling Changes with Methylphenidate Treatment 
Following intermediate treatment, (30 minutes after treatment), a significant 
interaction between strain/treatment (WKY saline, WKY MPH, SHR saline, SHR 
MPH) and type of event (rapid single, rapid multi, slow) was discovered 
(F6,52=7.311, p<0.0001). Significant effects of strain/treatment (F3,26=10.55, 
p=0.001) and type of event (F2,52=46.71, p<0.0001) were also found to exist. The 
WKY saline group had less of the rapid single peaks compared to the WKY MPH 
and SHR saline groups. The SHR MPH had significantly more of the rapid multi 
peaks compared to the WKY MPH and significantly more rapid multi and slow 
phasic events compared to the SHR saline group (Figure 5.11A). 
Following chronic treatment (30 minutes after treatment), a significant 
interaction between strain/treatment and type of event was found (F6,52=8.120, 
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p<0.0001). A significant effect of type of event (F2,52=97.79, p<0.0001) was also 
found. The SHR saline group was observed to have more of the rapid single peaks 
compared to the WKY saline and the SHR MPH groups. The SHR MPH had more 
slow phasic events than the SHR saline group (Figure 5.11B). An example of the 
three major types of phasic signaling are represented in Figure 5.11C-E. 
 
Discussion 
Methylphenidate (MPH) administration has been found to increase 
dopamine levels by blocking the dopamine transporter (DAT) (Kuczenski and 
Segal 1997, Gerasimov, Franceschi et al. 2000, Gerasimov, Franceschi et al. 
2000, Kuczenski and Segal 2001, Volkow, Wang et al. 2001, Huff and Davies 
2002, Marsteller, Gerasimov et al. 2002), as well as the norepinephrine transporter 
(NET) in the PFC (Gatley, Pan et al. 1996). The increase in dopamine is thought 
to be responsible for increased motor activity (Rebec 2006). Studies of signaling 
interactions between the dopaminergic and glutamatergic systems demonstrate 
that stimulation of D2 dopamine receptors is involved in the inhibition of the NMDA 
receptor, weakening the excitatory response to those neurons (Kotecha, Oak et al. 
2002). Likewise, activation of D4 receptors decreased AMPA receptors at the 
synapse (Yuen, Liu et al. 2010). Because of these links between the dopamine 
and glutamate systems, we sought to use a known dopaminergic-altering drug to 
examine the effects on the glutamatergic system. Moreover, the behavioral effects 
of a clinically relevant dose of MPH treatment are predictable and have been well 
established in the spontaneously hypertensive rat (SHR) model of ADHD (Wultz, 
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Sagvolden et al. 1990, Sagvolden, Metzger et al. 1992, van den Bergh, Bloemarts 
et al. 2006, Barron, Yang et al. 2009). We observed that total distance traveled 
increased in the SHR acutely and chronically following MPH. This increase in 
activity is consistent with behavioral sensitization in response to chronic MPH 
treatment (Crawford, McDougall et al. 1998), though the WKY control failed to 
reach sensitization levels. No challenge dose was used in this study, as has been 
done in previous work exploring MPH sensitization (Gaytan, al-Rahim et al. 1997, 
Crawford, McDougall et al. 1998, McDougall, Collins et al. 1999) and studies have 
shown that chronic administration alone isn’t enough to produce behavioral 
sensitization following low-dose MPH treatment (Suzuki, Shindo et al. 2007) and 
explains the lack of increased behavior in the control WKY strain following 11 
treatment days with MPH. However, the increase in activity of the hyperactive SHR 
assured that the low, clinically relevant dose of MPH used was appropriate to 
cause significant behavior effects in the ADHD model but not the control. 
The link between alterations in glutamate neurotransmission and 
substances of abuse have been well established in such drugs as cocaine 
(Pulvirenti, Swerdlow et al. 1989, Pulvirenti, Swerdlow et al. 1991, Witkin 1993), 
amphetamine (Pulvirenti, Swerdlow et al. 1989), and methamphetamine (Witkin 
1993). Given the role of glutamate on the addictive properties of these drugs, we 
sought to investigate the role of glutamate signaling following chronic MPH 
administration. The SHR model of ADHD self-administers cocaine more readily 
than the progenitor control strain, the WKY (Harvey, Sen et al. 2011). The results 
from the present study demonstrate that in the SHR model of ADHD, overall tonic 
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glutamate levels were higher in the MPH treated group than the saline treated 
SHRs. These observed increases of glutamate following MPH administration may 
then potentiate the responses for drug abuse later in life. Supporting this theory, 
the SHR was discovered to be more likely to self-administer cocaine as an adult 
than controls following chronic treatment with a clinically relevant dose of MPH 
(administered p.o.) at a young age (Harvey, Sen et al. 2011). Interestingly, SHRs 
chronically administered the non-stimulant atomoxetine as adolescents were no 
more likely to self-administer cocaine in adulthood than controls (Somkuwar, 
Jordan et al. 2013), demonstrating that non-stimulant medications represent an 
important alternative for treatment of ADHD. Future studies should examine if 
increases in glutamate are observed following chronic treatment with atomoxetine 
within the SHR. 
 In addition to increases in tonic glutamate following MPH in the SHR, we 
found that chronic MPH exposure decreased the amplitude of phasic glutamate 
signaling in the SHR but not the WKY control. The increase of tonic glutamate in 
the SHR model of ADHD following chronic MPH treatment does not cause an 
increase in the phasic release of glutamate, but instead decreases the phasic 
signaling amplitude. It is possible that the rise of tonic levels following MPH causes 
activation of more auto-receptors, attempting to compensate for the higher 
glutamate concentrations (Lin, Wang et al. 2000, Johnson, Niswender et al. 2011, 
Tang, Liu et al. 2013). Research has been focused on group II and III inhibitory 
metabotropic glutamate auto-receptors, linking them as possible therapeutic 
targets for anxiety (Swanson, Bures et al. 2005, Riaza Bermudo-Soriano, Perez-
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Rodriguez et al. 2012), schizophrenia (Hashimoto, Malchow et al. 2013), 
depression (Chaki, Ago et al. 2013), alcoholism (Holmes, Spanagel et al. 2013), 
and cocaine addiction (Li, Xi et al. 2013). The results from this study suggest that 
ADHD should now be included as a disorder that may benefit from targeting these 
auto-receptors, potentially as a co-treatment with stimulants if they are deemed 
effective. A recent study examining attention deficits caused by nicotine exposure 
during adolescence found reduced group II mGluRs in the PFC and an mGluR2 
agonist was found to restore attention upon maturation into adulthood (Counotte, 
Goriounova et al. 2011). These results suggest that targeting the inhibitory auto-
receptor to restore basal glutamate signaling could therapeutically benefit 
individuals with ADHD. Future research should examine the effects of mGluR 
group II and III agonists, such as LY354740 and related compounds (Hascup, 
Hascup et al. 2012, Koltunowska, Gibula-Bruzda et al. 2013, Wang, Li et al. 2013), 
and antagonists, such as LY341495 (Diraddo, Miller et al. 2014) on glutamate 
signaling as well as the effects on the ADHD-like behaviors of the SHR. 
 Along with the discovery that chronic MPH treatment reduced the amplitude 
of phasic glutamate signals in the SHR model of ADHD, different types of phasic 
signaling were observed and found to be changed following treatment with MPH. 
To our knowledge, this is the first time that phasic glutamate signaling has been 
able to be quantified as having different characteristics, though this is not the first 
time that phasic signaling has been observed in awake, freely-moving animals 
(Hascup, Hascup et al. 2011, Wassum, Tolosa et al. 2012). The SHR had more 
rapid single peaks, lasting about 10 seconds before returning to baseline, than the 
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WKY control after both intermediate and chronic saline (or vehicle) alone 
administration, suggesting that the SHR model of ADHD has higher activity of 
phasic glutamate events. In the SHR, intermediate MPH treatment was found to 
increase the rapid multi-peaks compared to the SHR saline group, whereas 
chronic MPH actually decreased these fast multi-peak phasic events in the SHR. 
Additionally, after chronic treatment with MPH, the SHR had more of the slow 
phasic type signals, which could take as long as 3 minutes before returning to a 
stable baseline. These signals seem to contribute more towards the changes in 
tonic glutamate than the other phasic signals and may explain why the SHR had 
increased tonic levels following MPH treatment. These data all suggest that 
targeting tonic and phasic glutamate may be a useful approach for novel ADHD 
treatments 
Conclusions 
These studies raise the exciting possibility that targeting group II and III 
mGluRs may provide a novel approach to treatment of ADHD without the adverse 
effects associated with currently available drugs. More importantly, these findings 
illuminate a pathway targeting glutamate dysfunction for investigating novel 
therapies for the treatment of ADHD. Future studies should examine the effects of 
current FDA-approved pharmacotherapies that are known to target the glutamate 
system, such as memantine and ceftriaxone, on the SHR model of ADHD. Using 
these medications, it may be possible to better treat ADHD in adolescents and 
adults without the negative side effects and abuse liability of current medications. 
Copyright © Erin Michelle Miller 2014 
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Chapter Five: Figures 
 
Figure 5.1 Experiment Timeline 
A) Each day started with the animal being placed into the behavior box to allow for 
one hour of baseline activity. A saline injection (s.c.) was used to determine any 
injection effects on behavior or glutamate. Glutamate levels were then assessed 
30 minutes post-saline administration. Next, either saline or MPH was given (s.c.) 
and three glutamate time-points were sampled. The experiment ended three hours 
after the 2nd injection. B) Experimental paradigm. The S2 MEA was implanted on 
day 0 and the animal was allowed two days to recover from surgery. On day three, 
glutamate and behavior recordings began. Behavior was completed each day in 
the open-field box, whereas glutamate recordings were performed on alternate 
days. 
 
 
 
 
 
139 
 
Figure 5.2 Percent Weight Change Post-MEA Implant 
A) The WKY strain treated with MPH weighed significantly more than the WKY 
group treated with saline alone during the last 4 days of the experiment, suggesting 
that MPH may have a protective effect in these animals. B) In the SHR, no 
differences were observed between the MPH and saline treated animals. *p<0.05. 
Mean ± SEM. 
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Figure 5.3 Total Distance Traveled: Acute Effect of Methylphenidate 
Baseline locomotion of the SHR and WKY strains was similar, as was the activity 
following saline (s.c.) administration (orange arrow). Beginning 30 minutes after 
treatment (green arrow, 2 mg/kg s.c.), the SHR treated with MPH for the first time 
(pink circles) had significantly increased total distance traveled than the SHR saline 
group (open black circles, *p<0.05) as well as the WKY treated with MPH group 
(blue triangles, xp<0.05). This effect lasted approximately 90 minutes. 1 minute 
bins. Mean ± SEM. 
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Figure 5.4 Total Distance Traveled: Intermediate Effect of Methylphenidate 
Baseline locomotion of the SHR and WKY strains was similar, as was the activity 
following saline (s.c.) administration (orange arrow). Beginning 30 minutes after 
treatment (green arrow, 2 mg/kg s.c.), the SHR treated with MPH (pink circles) had 
increased total distance traveled than the SHR saline group (open black circles, 
*p<0.05) as well as the WKY treated with MPH group (blue triangles, xp<0.05). This 
effect lasted approximately 120 minutes. 1 minute bins. Mean ± SEM. 
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Figure 5.5 Total Distance Traveled: Chronic Effect of Methylphenidate 
The SHR: MPH (pink) and SHR: saline (black) groups had increased locomotion 
during the first 5 minutes of baseline compared to both WKY groups (xp<0.05 vs. 
WKY: MPH; •p<0.05 vs. WKY: saline). The activity following saline (s.c.) 
administration (orange arrow) was similar between all groups. Beginning 30 
minutes after treatment (green arrow, 2 mg/kg s.c.), the SHR treated with MPH 
(pink circles) had increased total distance traveled than the SHR saline group (open 
black circles, *p<0.05). The SHR: MPH group also had increased activity than the 
WKY treated with MPH group (blue triangles, xp<0.05), beginning 90 minutes post-
MPH and this effect only lasted for approximately 30 minutes. 1 minute bins. Mean 
± SEM. 
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Figure 5.6 Glutamate Signal, Sentinel, and Behavior Traces 
A) An example of tonic and phasic glutamate signaling over the course of the 5 
hour experiment in one animal. The blue trace is the background subtracted 
glutamate signal which results in tonic glutamate levels. The black trace is the 
sentinel, or background noise and is included only to compare the signaling to the 
blue, thus the y-axis location is unimportant. Examining the blue trace compared 
to the black trace allows for the inspection of changes in phasic glutamate during 
the experiment. Total distance traveled (in 1 minute bins) is shown in the gray bars 
on the bottom. Orange arrow, saline (s.c.). Green arrow, methylphenidate (2 
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mg/kg, s.c.). The blue dashed box is represented in B. B) An example of tonic and 
phasic glutamate signaling post-MPH administration for 10 minutes. Comparing 
the blue trace to the black trace allows for changes in phasic glutamate during the 
experiment to be apparent. 3 major types of phasic signaling are apparent here: 
1) the pink oval arrow - fast multi-peaks, 2) the black pointed arrow - fast single 
peaks, and 3) the black half-circles – slow phasic signaling. 
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Figure 5.7 Strain Differences in Tonic and Phasic Glutamate Levels 
After baseline of the S2 MEA, strain differences were observed in tonic and phasic 
glutamate levels. Only the raw, background-subtracted glutamate signal is 
represented here. Black, WKY saline. Blue, WKY MPH. Grey, SHR saline. Pink, 
SHR MPH. Orange arrow, saline (s.c.). Green arrow, methylphenidate (2 mg/kg, 
s.c.). Purple arrow, applied voltage changed to +0.2 V vs. Ag/AgCl reference 
electrode. 
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Figure 5.8 Intermediate and Chronic Effects of MPH (2 mg/kg) Administration on 
Tonic Glutamate Levels 
A) The SHR MPH group (pink circles) had higher tonic glutamate than the SHR 
saline (open circles), and suggests that MPH causes the tonic levels of the SHR 
to be more similar to that of the WKY control (blue triangles), which had similar 
tonic levels when treated with MPH or saline (black triangles). Additionally, the 
WKY saline group had higher tonic glutamate than SHR saline. B) Following 
chronic treatment, both the SHR model of ADHD and the WKY control had 
increased tonic glutamate than animals treated with saline only. *p<0.05. Mean ± 
SEM. 
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Figure 5.9 Intermediate and Chronic Effects of MPH (2 mg/kg) Administration on 
Phasic Glutamate Signaling Frequency 
The number of phasic events per 10 minute sample did not differ between strain, 
treatment, nor time. 
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Figure 5.10 Intermediate and Chronic Effects of MPH (2 mg/kg) Administration on 
Phasic Glutamate Signaling Amplitudes 
A) No differences in the size of the phasic glutamate signals were apparent 
following intermediate treatment with MPH. B) Following chronic treatment, the 
SHR model of ADHD treated with MPH had lower phasic glutamate amplitudes 
compared to SHRs treated with saline. *p<0.05. Mean ± SEM. 
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Figure 5.11 Differences in Phasic Signal Types 
A) Following intermediate treatment, during the first 10 minute sample period (30 
minutes post-treatment), it was discovered that the WKY saline group had less 
rapid single peaks than the WKY MPH and SHR saline groups. The SHR MPH 
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had more rapid multi peaks compared to the WKY MPH and more rapid multi and 
slow phasic events than the SHR saline group. B) Following chronic treatment, 
during the first 10 minute sample period (30 minutes post-treatment), the SHR 
saline group had more rapid single peaks than the WKY saline and the SHR MPH 
groups. The SHR MPH had more slow phasic events than the SHR saline group. 
An example of the three major types of phasic signaling: C) fast single peaks, D) 
fast multi-peaks, and E) slow phasic signaling. *p<0.05. Mean ± SEM. 
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Chapter Five: Tables 
Table 5.1 Freely-Moving S2 Microelectrode Array Specifications 
 
 
WKY: 
Saline 
WKY: 
MPH 
SHR: 
Saline 
SHR: 
MPH 
Slope (pA/µM) 7.9 ± 0.70 6.8 ± 0.72 9.0 ± 1.2 8.1 ± 1.4 
Limit of 
Detection (µM) 
0.38 ± 0.046 0.75 ± 0.21 0.23 ± 0.055 0.43 ± 0.15 
No significant differences were observed in the performance of the S2 
microelectrode arrays used between strains. Mean ± SEM. 
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Chapter Six: Final Conclusions 
 The spontaneously hypertensive rat (SHR) model of attention-
deficit/hyperactivity disorder (ADHD) grants us the ability to investigate 
neurotransmitter system regulation in vivo in a diseased state. In this dissertation, 
we observed dysfunction in multiple brain regions as well as multiple 
neurotransmitters within these regions in the SHR brain. The ultimate goal of the 
described studies was to discover novel ways to treat ADHD with minimal side-
effects and clear long-term safety and efficacy. Aberrant dopamine (DA) regulation 
has long been thought to play a large role in the pathophysiology of ADHD, though 
studies examining DA in the SHR have been equivocal. In the first set of 
experiments, we demonstrated that the SHR model of ADHD combined type 
(ADHD-C) and the Wistar Kyoto (WKY) progenitor strain from Charles River 
Laboratories (WKY/NCrl), which has been suggested as a model of the ADHD 
predominantly inattentive type, have distinct differences in the regulation of DA in 
the striatum and nucleus accumbens core compared to the inbred WKY from 
Harlan Laboratories (WKY/NHsd) and the outbred Sprague Dawley controls. 
Further data presented in Chapter Two provides evidence for dopaminergic 
system dysfunction in the frontal cortex (FC). These results suggest that increased 
surface expression of DA transporters (DAT) may explain the more rapid uptake 
of DA in the striatum, nucleus accumbens core and FC of these rodent models of 
ADHD. While these studies are compelling, there is an increasing number of 
studies that suggest ADHD is not limited to purely DA dysfunction (Carrey, 
MacMaster et al. 2002, Lehohla, Kellaway et al. 2004, Jensen, Rinholm et al. 2009, 
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Ludolph, Udvardi et al. 2010, Dramsdahl, Ersland et al. 2011, Hammerness, 
Biederman et al. 2012). Because of this, we deemed it necessary to study other 
neurotransmitter systems in the SHR model of ADHD. 
 Recent proton magnetic resonance spectroscopy imaging studies in 
humans with ADHD are beginning to implicate a dysfunctional glutamate system 
in ADHD (Moore, Biederman et al. 2006, Moore, Frazier et al. 2007, Hammerness, 
Biederman et al. 2012) and it is becoming clear that glutamate may be playing 
some role in the pathophysiology of ADHD. Glutamate regulation in the SHR may 
be impaired, creating the possibility that targeting dopamine-glutamate interactions 
in this model of ADHD may prove useful with novel therapeutics. Understanding 
the role of glutamate in ADHD and drugs that can modulate it should open a new 
mechanism of action for the treatment of ADHD. Chapter Three characterized 
glutamate signaling in the striatum, nucleus accumbens core, and FC of the SHR 
model of ADHD and compared the results to the WKY control. Interestingly, we 
discovered that the SHR exhibited altered glutamate regulation compared to the 
WKY control; however, the most impaired region was the FC of the SHR, 
displaying aberrant glutamate release and uptake, suggesting that fully 
characterizing this glutamate-rich region could provide us the opportunity to 
discover new therapeutics to better treat ADHD. These results suggest that the 
glutamatergic system in the FC of the SHR model of ADHD is hyperfunctional and 
that targeting glutamate in the FC could lead to the development of novel 
therapeutics for the treatment of ADHD. 
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Recording glutamate in anesthetized animals provided information that the 
SHR had aberrant glutamate signaling compared to the control WKY strain and we 
wanted to extend these findings into the awake, freely-moving rodent to more 
accurately define these abnormalities and examine the effects of a common ADHD 
treatment on glutamate. Chapter Four was able to translate the findings of Chapter 
Three into the awake, freely-moving rodent. Microelectrode array technology, 
however improved over technologies used in the past, was limited in that it could 
only record glutamate dynamics in a vertical height of 333 µm. However, a novel 
probe became available that allowed for recordings in four separate regions along 
the dorsal-ventral axis in the brain each having a vertical height of 333 µm, 
broadening the recording areas available. This new technology was chronically 
implanted into the FC of the 8 week old SHR and WKY, allowing for glutamate 
recordings in real-time within the cingulate, prelimbic, infralimbic and dorsal 
peduncle cortices simultaneously. We were able to record both tonic and phasic 
glutamate in the SHR and WKY, as well as investigate the effects of chronic 
methylphenidate treatment using a clinically relevant dose. The results from these 
studies demonstrate that it is possible to record from multiple brain regions in 
awake, freely-moving rodents, though more studies need to be completed on 
characterizing the novel DSPR8 microelectrode array in vivo. As the project 
developed, we realized that the DSPR8 microelectrode arrays used were in need 
of improvements, so in order to complete the study to fully characterize glutamate 
levels in the awake rodent, we employed the glutamate-selective microelectrode 
array used in Chapter Three, thus limiting us to recording in the prelimbic region 
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only. However restrictive this was, the consistency and reliability of the 
microelectrode array used in the rest of the studies is superior to other 
commercially available in vivo neurochemistry recording devices.  
Chapter Five examined tonic and phasic glutamate changes in prelimbic 
cortex within the FC of the SHR model of ADHD and the WKY control strain. A 
clinically relevant dose of methylphenidate (2 mg/kg) or the vehicle saline were 
given for 11 days to evaluate acute, intermediate, and chronic effects on glutamate 
signaling, while simultaneously recording behavior, including locomotion. We 
chose locomotion in the open-field behavior task because it has previously been 
shown that the SHR displays hyperactive behavior in this task, similar to that seen 
in humans with ADHD. Additionally, we wanted a task that had been characterized 
using both the SHR and methylphenidate, as we were trying to find novel changes 
in glutamate. Future directions should include a less characterized but still relevant 
to ADHD behavior task, such as delayed discounting, while exploring changes in 
glutamate and the effects of pharmacology. Using the open-field task, we observed 
that methylphenidate significantly increased the total distance traveled in the SHR 
acutely but not the WKY. Chronically, only the SHR displayed increased total 
distance traveled after methylphenidate compared to the saline control group. 
Moreover, intermediate treatment (5 or 7 days) with methylphenidate increased 
tonic glutamate levels in the SHR only, whereas chronic methylphenidate (9 or 11 
days) increased tonic glutamate in both the SHR and WKY strains. Surprisingly, 
chronic methylphenidate treatment, at a clinically relevant dose, decreased the 
amplitude, or size, of the phasic glutamate signals compared to the saline treated 
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SHR group. This effect did not exist in the control WKY group treated with 
methylphenidate. These data suggest that methylphenidate, a DA reuptake 
inhibitor, has an effect on the glutamatergic system via normal dopamine-
glutamate interactions, possibly via auto-receptors on both the presynaptic and 
postsynaptic neurons.  
Overall, the SHR model of ADHD was characterized for both dopamine and 
glutamate dysfunction in multiple brain regions implicated in the etiology of ADHD. 
Although there is no perfect animal mode of ADHD, the results from the described 
experiments together demonstrate that the SHR model of ADHD is a great 
resource for understanding and studying dysfunction of ADHD-like behaviors. In 
this study, the stimulant medication methylphenidate increased locomotion in the 
SHR and these were in parallel to differences on the glutamate system. This 
finding gives us a pathway for investigating novel therapies for the treatment of 
ADHD targeting glutamate. 
Future studies should examine the effects of current FDA-approved 
pharmacotherapies that are known to target the glutamatergic system, such as 
memantine and ceftriaxone, on the glutamate and dopamine systems of the SHR. 
Additionally, the results from Chapter Five suggest that targeting the metabotropic 
glutamate receptors may be a useful therapeutic avenue for ADHD. These studies 
raise the exciting possibility that targeting group II and III mGluRs may provide a 
novel approach to treatment of ADHD without the adverse effects associated with 
currently available drugs. Because of these studies in the SHR rodent model of 
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ADHD, it may be possible to better treat ADHD in adolescents and adults without 
the negative side effects and abuse liability of current medications. 
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